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Chapter 1 
Introduction 
Dementia is a frequent disorder in the elderly. It is also a distressing condition both for 
the patient and caregiver. Dementia puts a high claim on health care costs. In the 
Netherlands about one tenth of the yearly health budget is spent on nursing homes. 
Dementia is the. main diagnosis in 40% of nursing home patients and coexisting 
dementia may be the underlying. motive for admittance to a nursing home in patients 
with other diseases. 1•2 The need for dementia care will probably grow since the elderly 
population is increasing both in percentage and in absolute number. J,4 
Reliable estimates of the frequency of dementia are important. Prevalence 
figures are used by health planners to determine the demand for disease-specific 
services. The incidence rate is morc informative when etiologic questions are addressed. 
For assessment of prevalence and incidence of dementia one cannot rely on medical 
registers; the disease is rarely reported on death celiificates and usually mild cases are 
not recognised. Therefore we studied the prevalence (chapter 2.1) and incidence 
(chapter 2.2) of dementia in a population-based study by active screening of 
participants. This study formed p31i of the Rotterdam Study, a prospective cohort study 
on medical disorders in the elderly.s 
Previous epidemiologic studies suggested that not all social layers are equally 
affected by dementia.6 Especially lower educated people might be more susceptible. 
Therefore, we examined the association between education and prevalent dementia 
(chapter 2.1) and also assessed if lower educated were at higher risk of incident 
dementia (chapter 2.3). 
The lack of knowledge on Causes of dementia, especially Alzheimer's disease, 
motivated the second pm of this thesis.7 We mainly studied associations with other 
COlfunon disorders of old age that have vascular implications. This choice followed the 
notion that vascular disorders may play a role in cognitive decline and may be more 
impOliant in Alzheimer's disease than previously thought." Chapters 3.1 and 3.2 
describe studies on the relation between diabetes mellitus and dementia, both in 
prevalent and incident cases. In chapter 4.1 the association between atrial fibrillation 
and dementia is described. Also, several measures of atherosclerosis were studied in 
relation to dementia (chapter 4.2). Smoking is a major risk factor of cardio- and 
cerebrovascular disease.9 However, previous studies found an inverse association 
be(ween smoking and Alzheimer's disease. 10 Therefore we studied the risk of incident 
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dementia in relation to smoking habits (chapter 4.3). In the last chapter of this thesis, I 
integrate and discuss all findings, with special reference to prevalence-incidence bias, 
and make suggestions for future research (chapter 5). 
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Chapter 2.1 
The prevalence of dementia, Alzheimer's disease, and 
vascular dementia: the association with education 
Abstract 
II 
Objective: To estimate the prevalence of dementia and its subtypes in the general 
population and to study the relation with education. Design: Population-based, 
cross-sectional study. Setting: Ommoord, a suburb of Rotterdam, the Netherlands. 
Subjects: 7528 pmticipants of the Rotterdam Study, aged 55 to 106 years. 
Results: The prevalence of dementia was 6.3%, ranging from 0.4% in subjects aged 
55-59 years to 43.2% in those aged 95 years mId over. Alzheimer's disease was the 
major subdiagnosis (72%); it also was the main cause of the strong increase of 
dementia with age. The relative proportion of vascular dementia (16%), Parkinson's 
disease dementia (6%) and other dementias (5%) decreased with age. A significantly 
higher prevalence of dementia was found in subjects with a low level of education. The 
association with education was not due to confounding by cardiovascular disease. 
Conclusions: The prevalence of dementia increases exponentially with age. About 
one-third of the population of 85 years and over suffers from dementia. Three-qumters 
of all dementia is due to Alzheimer's disease. In this study an inverse dose-response 
association was found between education and dementia, in particular Alzheimer's 
disease. 
Introduction 
In many populations the proportion of elderly people is growing steadily. Owing to 
shifts in the population pyramid and increasing life expectancy the number of people 
aged 75 mId older in the Netherlands has increased by 65% in the past 20 years.' 
Similar increases have occurred in other countries and will have a major impact on 
future health care costs.2 Dementing disorders are common in elderly and especially 
ve,y old people.3 Studies of their prevalence rates and determinants are of medical and 
social impol1ance. 
We studied the prevalence of dementia and its subtypes among 7528 subjects in 
the population based Rotterdam Study, with special reference to its association with 
level of education. 
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Population and Methods 
The Rotterdam Study is a prospective population based study of several important 
groups of diseases of old age4,5 -namely, neurological, cardiovascular, locomotor and 
ophthalmological. Between 1990 and 1993 aU participants were subjected to detailed 
interview and examination in order to coUect baseline data and to ascertain their health 
status. In a substudy the prevalence of dementia was assessed by a three phase 
approach. Firstly aU participants were screened with a brief cognitive test. Screen 
positive subjects then undenvent additional testing, and those whose results suggested a 
possibility of dementia were either subjected to detailed examinion or had their medical 
records used to conftrm the diagnosis and establish the type of dementia. 
STUDY POPULATION 
AU residents of the Rotterdam suburb of Ommoord aged 55 years and over (including 
those living in institutions) were invited to participate in the Rotterdam Study. Of the 
10275 eligible subjects, 7983 (78%) accepted. Of the eligible subjects, 7528 (73%) 
were screened for cognition in the dementia study, the remaining subjects being lost 
through deaths or refusal. 
MEASUREMENTS 
The brief cognitive test for dementia comprised a combined minimental state 
examination6 and geriatric mental state schedule (GMS-A, organic level).1 The test was 
administered by trained research assistants. Screen positive subjects had a minimental 
state examination score of 25 or less or a geriatric mental state score of 1 Of more. 
Screen positive subjects were subsequently examined by a physician with the 
CAMDEX (Cambridge examination for mental disorders .of the elderly) diagnostic 
interview,8 which included an interview with an informant. P31iicipants who scored less 
than 80 on the CAMDEX cognitive test or who had higher scores but were suspected of 
dementia clinically were asked to pat1icipate in a third, extensive examination. In this 
diagnostic phase they were examined by a neurologist, had a brain scan (by magnetic 
resonance imaging), and were tested by a neuropsychologist. 
Of screen positive subjects, 92% undenvent the CAMDEX diagnostic interview, 
Many subjects with dementia were resident in six homes for elderly people, which were 
included in the study. These homes had psychogeriatric dep31tments. Often subjects 
were already known to be demented. Of these subjects and of 8% of the screen positive 
subjects who refused the CAMDEX interview or could not be examined, diagnostic 
infoffilation was obtained from the general practitioner, physicians in the homes, 
neurologists or the Rotterdam Regional Institute for Outpatient Mental Health Care. 
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During the initial interview the attained level of education was assessed 
according to the standard classification of education,9 comparable to the international 
standard classification of education (UNESCO, Paris, 1976). In the standard 
classification of education seven levels are recognised. In our analysis we combined the 
4 highest levels into one reference category, thus obtaining 4 levels: (1) primary 
education, this applied to 26% of the pmiicipants, (2) low level vocational training 
(20%), (3) medium level secondary education (15%), (4) medium level vocational 
training to university level (39%). 
Three indicators of cardiovascular disease (stroke, myocardial infarction and 
peri feral atieriosclerotic disease), as described in detail elsewhere,1O were examined as 
possible confounders in the relation between education and dementia. A history of 
stroke was determined through interview or infonnant interview in dementia patients. 
Confllmation of the stroke by a treating physician was required. A previous myocardial 
infarction was assessed on an electrocardiogram. Suspected abnormalities according to 
preset criteria were all reviewed by a cm·diologist. The presence of peripheral 
atherosclerotic disease was assumed if the ankle-aim index (ratio between tibial and 
brachial systolic blood pressure), measured in supine position, was less than 0.9 on at 
least one side. 
DIAGNOSIS OF DEMENTIA 
For the diagnosis of dementia DSM-III-R criteria were used. tI The sUbdiagnosis of 
Alzheimer's disease was based on NINCDS-ADRDA criteriaY Both possible and 
probable Alzheimer cases were grouped in this categOtY. For the sUbdiagnosis of 
vascular dementia the DSM-III-R defmition of multi-infarct dementia was used. 
The dementia type at the onset of the disease was ascetiained. Some Alzheimer 
patients develop symptoms of vascular dementia in the course of the disease, usually 
following a stroke, which may result in a sudden worsening of dementia.1l We 
classified these patients as Alzheimer's type with cerebrovascular disease. Parkinson's 
disease dementia was diagnosed when the dementia stmied after the onset of idiopathic 
parkinsonism. The three most important other dementias were alcohol-related dementia, 
tumour-related dementia and dementia associated with normal pressure hydrocephalus. 
In five patients insufficient infonnation was available to make a subdiagnosis. 
On the basis of the Clinical Dementia Rating scale (CDR)" and the MMSE 
score a division was made between severely impaired (CDR above 2 or MMSE below 
15, hereafter referred to as 'severe dementia') and mild to moderately impaired. In the 
overall prevalence figures all dementia cases, from mild to severe, are included. 
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DATA ANALYSIS 
The prevalence of dementia and its subtypes was calculated as the percentage of 
dementia by gender and 5 year age strata. Multivariate logistic regression was used to 
analyze the association between educational status and dementia. The odds ratio as 
estimated fl:om the logistic model was used as our measure of association, and referred 
to as "relative risk". With dementia or one of the subtypes of dementia as outcome 
variable we compared the levels of education, adjusted for age (numerical variable) and 
gender. The highest education level (category 4) was used as reference. The trend in the 
relative risk for dementia by education was tested with level of education as a linear 
trend variable in the logistic regression analysis. 
By adding either stroke history, myocardial infarction or peripheral 
atherosclerotic disease as covariates in the logistic regression model we checked if these 
cardiovascular indicators caused substantial changes in the relative risks, associated with 
the various levels of education. 
Results 
In Table 1 the number of participants in the dementia study is presented, as well as 
their distribution according to age and living conditions. Of the 7528 study participants 
474 were demented (6.3% in total, 3.8% of the men and 7.9% of the women). Age and 
gender specific prevalences of dementia are given in Table 2 and visualised in Figure I. 
With the exception of the age-category of 80-89 years there were no major differences 
in prevalence between men and women. In those aged 80-89 women had a higher 
prevalence then men. About one third of all demented persons had severe dementia; this 
applied to both men and women. 
TABLE 1. Characteristics of the study popUlation. 
Women 
Number eligible 6325 
Participants in the Rotterdam Study 4878 (77%) 
Included in the dementia prevalence study 4589 (73%) 
Age range (median) 55-106 (70) 
Percentage living in institutions 15% 
Men 
3950 
3105 (79%) 
2939 (74%) 
55-97 (68) 
6% 
Total 
10275 
7983 (78%) 
7528 (73%) 
55-106 (69) 
12% 
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TABLE 2. Prevalence of dementia per age category. 
Age category Women Men Total 
% (Numbers) % (Numbers) % (Numbers) 
55 - 59 years 0.6 (4/688) 0.2 (1/493) 0.4 (5/1181) 
60 - 64 0.4 (3/807) 0.5 (3/625) 0.4 (6/1432) 
65 - 69 1.0 (7/735) 0.8 (5/624) 0.9 (12/1359) 
70 - 74 2.1 (151712) 2.0 (10/492) 2.1 (2511204) 
75 - 79 6.2 (37/597) 6.0 (22/365) 6.1 (59/962) 
80 - 84 19.3 (92/477) \3.7 (28/204) 17.6 (120/681) 
85 - 89 32.7 (1\8/361) 28.4 (29/102) 31.7 (147/463) 
90 + 40.6 (86/212) 41.2 (14/34) 40.7 (100/246) 
Total 7.9 (362/4589) 3.8 (112/2939) 6.3 (474/7528) 
Prevalences of Alzheimer's disease, vascular dementia, Parkinson's disease 
dementia and other dementias are given in Figure 2. Overall, 72% of the dementias 
were of the Alzheimer's disease type, 16% were vascular dementia, 6% were 
Parkinson's disease dementia and 5% were other dementias. Table 3 shows the gender 
specific prevalence and number of cases of the types of dementia in IO-year age strata. 
There were no substantial differenc~s between men and women in prop0l1ions of 
dementia types. 
Prevalence (%) 
40-
30 
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60 65 70 
Total 
demenUa 
... ···s~vere 
. dementia 
75 80 85 90 95 
Age (years) 
-Women 
"'Men 
Figure 1. Prevalence of 
total dementia and severe 
dementia plotted at the 
mcan age of each five year 
age category. 
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TABLE 3. Prevalence of Alzheimer's disease, vascular dementia, Parkinson's disease 
dementia aDd other dementi as. • 
Age Women Men Total 
category % (N) %(N) %(N) 
Alzheimer's disease 55-64 0.1 (2) 0.2 (2) 0.2 (4) 
65-74 1.0 (15) 0.8 (9) 0.9 (24) 
75-84 8.4 (90) 5.4 (31) 7.4 (121) 
85+ 27.2 (156) 25.0 (34) 26.8 (190) 
Total 5.8 (263) 2.6 (76) 4.5 (339) 
Vascular dementia 55-64 0.2 (3) 0.2 (2) 0.2 (5) 
65-74 0.2 (3) 0.3 (3) 0.2 (6) 
75-84 2.0 (22) 2.1 (12) 2.1 (34) 
85+ 4.9 (28) 2.2 (3) 4.4 (31) 
Total 1.2 (56) 0.7 (20) 1.0 (76) 
Parkinson's disease dementia 55-64 0.1 (I) (0) 0.04 (1) 
65-74 0.1 (2) 0.1 (1) 0.1 (3) 
75-84 1.0 (II) 0.4 (2) 0.8 (13) 
85+ 1.7 (10) 2.2 (3) 1.8 (13) 
Total 0.5 (24) 0.2 (6) 0.4 (30) 
Other dementias 55-64 0.1 (I) (0) 0.04 (I) 
65-74 0.1 (2) 0.2 (2) 0.2 (4) 
75-84 0.6 (6) 0.9 (5) 0.7 (II) 
85+ 0.9 (5) 2.2 (3) l.l (8) 
Total 0.3 (14) 0.4 (10) 0.3 (24) 
* 5 undetennined cases are excluded from these figures 
The level of education was related to dementia. As shown in Figure 3 the 
relative risks (adjusted for age and gender) decreased with increasing educational status. 
Among people with the two lowest levels of education significantly more dementia was 
diagnosed than among those with the highest level of education (relative risks: 3.2 
(95% CI: 2.2-4.6) and 2.0 (1.3-3.2), respectively). Similarly for Alzheimer's disease the 
two lowest educational levels had increased relative risks: 4.0 (2.5-6.2) and 2.3 (1.3-
4.1), respectively. For vascular dementia only the lowest educated were at significantly 
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Figure 2. Prevalences of 
Alzheimer's disease, vascu~ 
lar dementia, Parkinson's 
disease dementia and other 
dementia's plotted at the 
mean age of each five year 
age category . 
Figure 3. Association of level 
of education with subtypes of 
dementia (adjusted for age 
and sex) expressed as odds 
ratios and 95% confidence 
intervals (bars). Level 4 is 
the reference level. 
increased risk: 2.1 (1.0-4.5). Other dementias, including Parkinson's disease dementia, 
were not significantly associated with education. The trend of higher dementia 
prevalences with less education was highly significant (p<0.000 I). Similar trends were 
observed for Alzheimer's disease and vascular dementia (p<0.0001 and p~O.OI, 
respectively). 
Adding either one or a combination of the indicators of cardiovascular disease 
did not decrease the inverse relation between educational status and dementia, 
suggesting that the presence of cardiovascular disease does not explain the association 
between dementia and education. 
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Discussion 
We presented detailed age specific prevalences of dementia and dementia subtypes, 
indicating Alzheimel"s disease as the main contribution to the exponential increase of 
dementia with age. Our data also showed the consistent trend of a higher risk of 
dementia with lower education. This effect of educational status could not be explained 
by a confounding effect of cardiovascular disease. 
All recent population-based studies on the prevalence of dementia with 
standardised diagnostic criteria show an exponential increase with age and a 
predominance of Alzheimer's disease as the cause of the dementia. However, age 
specific prevalences still vary considerably between studies. This may be due to the 
study design, the population sampling method or real geographic variations. The present 
study is the largest European study of its kind, thereby allowing more precise estimates 
of prevalence. Compared with a pooled reanalysis of 12 European studies,3 we found 
slightly lower prevalences below the age of 75 years and slightly higher prevalences 
above the age of 80 years. Differences in the screening properties and the type of 
population are the most likely causes. A .high sensitivity and specificity of the 
diagnostic procedure was ensured by the three phase comprehensive diagnostic 
work-up.15 A major concern in prevalence studies is non-participation, The Rotterdam 
Study, of which the dementia study was only a part, had a relatively high participation 
rate (almost 80%). However the non-response may have been selective. If non-response 
has distOlied the study results, it probably produced an underestimate of the prevalence 
of dementia. We consider it not very likely that the non-response has influenced the 
relative propOliions of subtypes of dementia. 
Without autopsy confilmation, subtyping dementia remains unceliain. Also, the 
cun'ent diagnostic criteria that we used have a limited accuracy, a fact which all large 
population based dementia studies have to face, even if we could base the subdiagnoses 
on a great number of reliable data. Alzheimer's disease was the mam contributor to the 
steep increase of dementia prevalence with age. In fact, we observed only little increase 
with age in vascular dementia and even less in Parkinson's disease dementia and other 
dementias. We classified primary Alzheimer's disease complicated with 
cerebra-vascular disease, as Alzheimer's disease. This may be why we a found a 
somewhat higher prevalence of Alzheimer's disease than other European studies. 16 
This study shows, as others did, a higher prevalence of dementia in groups with 
less education. 17-21 It has been suggested that the education effect could be due to a 
diagnosis bias. There is indeed a possibility that an early dementia in a highly educated 
person has been missed, although we do not think it likely that this has happened often 
because the combined MMSE/GMS screening test is very sensitive. 15 The finding that 
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the education effect also applies to vascular dementia, led us to consider whether the 
association of education with dementia may be due to confounding by cardiovascular 
disease. This is possible since cardiovascular disease is associated with both education 
and dementia: pat1icularly vascular dementia, but also Alzheimer's disease, are 
cOlTelated with cardiovascular disease,I3,22,23 and cardiovascular pathology is more 
prevalent in people with less education.24•25 However, control for possible confounding 
by cardiovascular disease did not substantially decrease the magnitude of the association 
of education with dementia; nor with subtypes of dementia. 
In conclusion, this large population-based study suggests that the prevalence of 
Alzheimer's disease strongly increases with age and that dementia, in pmlicular 
Alzheimer's disease, is inversely related with educational status. 
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Chapter 2.2 
The incidence and risk of dementia 
Abstract 
To assess age-, sex-, and subtype-specific incidence rates of dementia and to calculate 
the risk of dementia, the authors performed a large conmmnity-based, prospective 
COhOli study on dementia, as part of the Rotterdam Study. Participants were recruited 
among residents of a suburb of Rotterdam, aged 55 years and older. Baseline 
examinations took place between 1990 and 1993. The average follow-up was 2.1 years. 
Screening for dementia followed a three stage protocol. Medical records were evaluated 
of subjects who had died or could not be examined in person. Of 7,046 subjects who 
were non-demented at baseline, 162 developed dementia, during 15,135 person-years of 
follow-up, resulting in an overall incidence rate of 10.7 per 1000 person-years. From 
the youngest to the oldest 5-year age-category the incidence rate increased from 0.6 to 
97.2 per 1000 person-years. Only in men the increase levelled off after age 85. Overall, 
the incidence rate per 1000 person-years was 7.7 for Alzheimer's disease and 1.5 for 
vascular dementia. Dementia incidence rates and dementia-free Kaplan-Meier survival 
tables were used to calculate age- and sex-specific cumulative risks of dementia. 
Although the incidence rates of men and women up to age 85 were similar, the lifetime 
risk of dementia for 55 year old women was twice as high as for men (0.33 versus 
0.16), reflecting both higher life-expectancy of women and a higher dementia risk at 
very old age. 
Introduction 
Dementia is a major disabling disease in elderly people. Besides personal suffering of 
patients the disease may induce immense distress among family and care-givers. Many 
elderly people fear imminent dementia, yet few can imagine the actual risk of the 
disease. Most studies on the OCCUlTence of dementia in the general population were 
cross-sectional studies leading to prevalence figures, which are influenced by disease 
duration. Reliable figures of the age- and sex-specific incidence rates of dementia are 
still scarce. I Incidence rates reflect the probability of getting dementia conditional on 
being alive. These rates are based on the experience of a popUlation. Of more interest 
on the individual level is a person's absolute (unconditional) risk to develop dementia 
22 Incidence of dementia 
in the next few years, or io the rest of his or her life. To calculate these absolute risks, 
the competing risk of dying should be taken ioto account. 
We performed a large prospective study on the iocidence of dementia in the 
community, which enabled us to calculate period and lifetime risks to develop 
dementia. 
Materials and methods 
STUDY DESIGN 
The Rotterdam Study is a community based prospective cohort study io which several 
chronic diseases of the elderly are iovestigated.2 The study focuses on neurological, 
cardiovascular, locomotor and ophthalmologic diseases. The study was approved by the 
Medical Ethics Committee of Erasmus University/Academic Hospital Rotterdam. 
Infonned consent and pennission to retrieve information from treatiog physicians was 
obtained of all pm1icipants. 
Between 1990 mId 1993 participants were ioterviewed at their homes and 
thereafter, during two sessions, examined at the research center, in order to asceliain 
their health status and to collect baseline data. Follow-up examioations took place from 
mid 1993 to the end of 1994. 
STUDY POPULATION 
The study was conducted in Ommoord, a suburb of the city of Rotterdam, the 
Netherlands. At baseline, all inhabitants of this suburb aged 55 years and older, 
iocludiog those liviog io institutions, were invited to participate. Of 10,275 eligible 
subjects, 7,983 (78%) agreed to take part in the study and 7,528 (73%) were screened 
and examioed for dementia.3 Of these, 474 subjects were diagnosed to be demented. 
Eight persons whose dementia status at baseline was unce11ain were excluded from the 
follow-up analyses. This resulted in a cohOlt of 7,046 subjects at risk for dementia. At 
follow-up, 5,571 (79%) pa11icipants were re-screened for dementia, 476 (7%) subjects 
had died before screeniog, and io 999 (14%) subjects information was obtained through 
general practitioners and medical records. 
DEMENTIA CASE-FINDING 
Dementia screening and diagnosis at baseline and follow-up followed the same three 
step protocol. Firstly, with a combioed Mini Mental State Examination (MMSE)4 and 
Geriatric Mental State schedule (GMS-A, organic level),s the population was screened 
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for dementia. This test was administered by trained research assistants. Secondly, 
subjects scoring below 26 on the MMSE or more than 0 on the GMS were considered 
screen-positive and were subsequently examined by one of four study physicians with 
the CAMDEX diagnostic interview,6 which includes an informant interview. Finally, 
participants who were judged to be demented or suspected of dementia after the 
CAMDEX were examined by a neurologist, were tested by a neuropsychologist and had 
a brain nuclear magnetic resonance imaging scan made. Of patticipants whose dementia 
work-up was not complete, additional information was obtained from medical files. 
In addition to the dementia screening, the total cohOlt was continuously being 
monitored for detection of interval cases of dementia through linkage of the general 
practitioner's automated medical record system to the data base of the Rotterdam Study. 
All reports of incident events including onset of memory problems or dementia were 
regularly evaluated by the study physicians. Of non-respondents to the follow-up 
examination who were reported with memory problems or dementia, information was 
obtained from informants and medical files in order to make a diagnosis of dementia. 
Also, the regional institute for outpatient mental health care (RIAGG), covering the 
entire study population, provided information. This psychiatric service can both directly 
and by refenal be consulted for social and psychiatric problems and is responsible for 
nursing home or other dementia-care-facility indications. Their diagnoses are based on 
(informant) interviews, neurologic and neuropsychologic examination, and relevant 
blood biochemistry and serology. From this service, once a year information was 
obtained on newly diagnosed dementia or amnestic syndrome in study participants. 
Surveillance of the population through the general practitioners and RIAGG reports 
continued up to the end of 1994. 
The study diagnosis of dementia was made by a panel that reviewed all existing 
infOlmation. A diagnosis of Alzheimer's disease was based on National Institute of 
Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and 
Related Disorders Association criteria.7 According to those criteria a subdivision into 
possible and probable Alzheimer's disease was made. Vascular dementia was diagnosed 
in accordance with National Institule of Neurological Disorders and Stroke and 
Association Internalionale pour fa Recherche et ['Enseignemellt ell Neurosciences 
criteria.8 As proposed in the latter criteria we also categorized a subgroup of 
Alzheimer's disease with cerebrovascular disease. For other dementias, the Diagnostic 
alld Statistical Manual of melllal disorders (3rd ed., revised) dementia criteria were 
used.9 
The highest achieved level of education was assessed during the initial home 
interview. To adjust for education we categorized educational level into six grades. 
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DATA ANALYSIS 
The age-specific incidence was obtained per 5-year age-band by dividing the number of 
cases by the number of person-years, calculated by adding up each paliicipant's 
contribution of follow-up time per age-band. The follow-up period ended either at the 
second screening, at age at onset of dementia, or at death. For both screened and 
repOlied cases, the age at onset of dementia was taken to be the midpoint between 
baseline age and age at diagnosis. Of subjects without a second screening, follow-up 
through the repOlis fi'om treating physicians continued up till the end of 1994. 
incidence figures were estimated by gender, by dementia subtype and response status. 
Poisson standard elTOrs and 95% confidence intervals (95% el) were calculated from 
the number of incident cases per follow-up period. The difference in incidence between 
groups of subjects was expressed as a rate ratio, which was calculated with propOliional 
hazards regression, adjusting for age and if applicable other variables. 
To calculate the risk to develop dementia over time, competing risk of death was 
taken into account. Using incident dementia and mOliality data from the study cohort, 
we first made dementia-free survival functions with the Kaplan-Meier method. 1O Age at 
baseline was used as entry time variable, age at follow-up, dementia .onset, or death as 
exit time, and both incident dementia or death as failures. Next, the cumulative absolute 
risk of dementia over a period was composed as the integrated product of the age-
specific dementia incidence times the dementia free survival (reference 10, fOlTImla 
7.10, page 169). These risks to develop dementia were calculated separately for men 
and women at ages of 55, 65, 75, and 85 years. 
Results 
In table I several characteristics of the study population are summarized. Of the total 
COhOli (n=7,046) at risk to develop dementia, 79% was screened in person for 
dementia. Of those who were not examined at follow-up and of whom information on 
dementia was solely obtained through general practitioners and the RIAGG, 476 had 
died and 999 refused the screening tests. The propOliion of subjects who were not 
examined in person increased with age from 9% in the youngest to 45% in the oldest 
age-category and was in all age-groups somewhat higher in women than in men. 
MOliality lVas higher among men. 
Overall, after an average follow-up period of 26 months, 162 new cases of 
dementia were identified, 109 in the group examined in person and 53 through the 
general practitioner and RIAGG monitoring. The age- and sex-specific incidence is 
given in table 2. With a total of 15,135 follow-up years the overall incidence was 
TABLE 1. Characteristics of participants in the study on dementia incidence. This study was conducted in a population-based sampl~ aged 55 
years and over, as part of the Rotterdam Study, 1990-1994. 
Number (% of total) 
Women (%) 
Baseline age (SD) 
Primary education or less (%) 
Baseline MMSE score (SD) 
Total 
cohort 
7046 
59.9 
69.5 
24.1 
27.6 
(9.1) 
(1.9) 
Examined 
in person 
5571 (79.1) 
58.8 
68.1 (8.3) 
20.6 
27.& (1.&) 
No in person examination during 
follow-up * 
999 (14.2) 
6&.9 
72.6 (9.7) 
36.& 
27.0 (2.2) 
Adjusted difference 
(95% CI) t 
9.0 (5.8 to 12.4) 
-0.6 (-0.7 to -0.4) 
Died before follow-up examination * 
476 
54.6 
79.9 
41.5 
(6.&) 
(9.0) 
26.5 (2.7) 
Adjusted difference 
(95% CI) t 
4.4 (0.2 to 9.0) 
-0.6 (-0.& to -0.4) 
* Infonnation through general practitioners, the regional institute for outpatient mental health care and medical files. 
1" To adjust for age, sex.. and education (in case of the 11MSE), both groups were included in a logistic (for education) or linear (MMSE) regression 
model. The adjusted difference (and 95% CI) between both groups was calculated from the group coefficient (and standard error). 
CI: confidence interval, 11MSE: minimental state examination, SD: standard deviation. 
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TABLE 2. Age- and sex-specific number of person-yean at risk (Pyl's), number of dementia 
cases (N) and incidence ratcs (pCI' 1000 person-years, with 95% confidence interval) in a 
Dutch general population, the Rotterdam Study, 1990-1994. 
Age category 
(years) Pyes 
55 - 59 988 
60 - 64 1611 
65 - 69 1591 
70 - 74 1683 
75 - 79 1404 
80 - 84 1031 
85 - 89 695 
90 - 94 263 
;:, 95 63 
Total 9329 
CI: confidence interval 
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Age category 
Men 
Pyrs N Rate 95% CI 
707 1.4 0.2 - 10.0 
1142 0.9 0.1 - 6.2 
1269 I 0.8 0.1 - 5.6 
1110 5 4.5 1.9 - 10.8 
813 12 14.8 8.4 - 26.0 
479 12 25.1 14.2 - 44.1 
210 6 28.6 12.9 - 63.7 
67 2 29.6 7.4 - 118.5 
9 0 0.0 0.0 - 333.0 
5806 40 6.9 5.1 - 9.4 
Figure 1. Age specific dementia 
incidence of other studies 
compared to results from the 
present Rotterdam Study, 
conducted ill a Dutch general 
popUlation of SS years and 
older, between 1990 and 1994. 
10.7 per 1000 person-years. The incidence increased strongly with age. Though the 
overall incidence was higher in women than men (13.1 versus 6.9 per 1000 person-
years), age-specific incidence rates were very similar up to the age of 85 years. From 
that age onwards the incidence in men seemed to level off whereas in women it 
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continued to rise. However, in the highest age-categories in men, incidence estimates 
were based on small numbers of cases and person-years of follow-up and the 95% 
confidence intervals overlapped those for women of the same ages. Figure 1 shows the 
age-specific incidence among the total cohOlt compared with other incidence studies. ll-
13 In this figure only studies are included which were relatively large, used similar 
procedures to diagnose dementia at baseline and follow-up and calculated 5-year age-
specific incidence rates of total dementia. 
Comparison of the incidence between the in-person screened and those whose 
information on dementia status came from informants and medical files, revealed that 
there was no major difference up till the age of 85. Above age 85 more demented 
persons were identified by personal examination than by evaluation of reported possible 
patients (76. I per 1000 person-years versus 31.3 per 1000, respectively, with age and 
sex adjusted ratio of 0.5 (95% CI: 0.3-0.8). The difference in incidence between men 
and women could not be explained by differences in screening method. 
A dementia subtype was detelTIlined in 158 cases (98%). Alzheimer's disease 
was diagnosed in 116 (73%); 69 of those had probable Alzheimer's disease and 47 
possible Alzheimer's disease of whom 19 with cerebrovascular disease. Vascular 
dementia was detected in 22 (14%) and other dementias in 20 (13%). Proportions of 
dementia subtypes differed between men and women: of male cases, 58% was 
diagnosed as Alzheimer's disease and 23% as vascular dementia; of female cases these 
proportions were 79% and 11%. Overall incidence rates for Alzheimer's disease and 
vascular dementia in men were 4.0 and 1.6, and in women 10.0 and 1.4 per 1000 
person-years, respectively. Though age-adjusted rates of total dementia did not differ 
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Figure 3. Kaplan-Meier survival with and without dementia, and the cumulative risk of 
dementia (competing risk of death taken into account) of 55 year old women and men, as 
observed in the Rotterdam Study, 1990 - 1994. 
significantly between men and women, women were more often diagnosed with 
Alzheimer's disease than men (rate ratio: 1.7, 95% CI: 1.0-2.6). Men more often 
developed vascular dementia than women, though this difference did not reach 
significance (rate ratio: 1.6, 95% CI: 0.6-3.8). Figure 2 shows the age-specific 
incidence of subtypes of dementia for both sexes combined. The Alzheimer's disease 
incidence increased strongest with age. The incidence of vascular dementia also 
increased up to the oldest age categories, whereas the incidence of other dementias 
remained relatively stable with age. 
Figure 3 shows survival and dementia-free survival as observed in the total study 
cohOl1. The area between these curves represents the average time people live while 
demented. This area is clearly larger in women than in men, suggesting that overall 
women suffer more life-years from dementia than men. According to these data, we 
estimated that fifty-five year old women on average will be demented during the last 
2.5 years of their life. For men of this age the life expectancy with dementia is 1.2 
years. Figure 3 also includes the cumulative absolute risk for dementia of 55 year old 
men and women. Table 3 gives 5 to 40 year period as well as lifetime risks of 
deinentia. This table shows, for example, that 55-year old non-demented women have a 
9.9% risk to become demented within a period of 25 years, and a 32.6% lifetime risk. 
For men, who are at much higher risk of dying, the cOlTesponding figures are 7.7% and 
15.9%. 
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TABLE 3. Period and lifetime risk (percent) of dementia (competing risk of death taken into 
account) for 55, 65, 75 and 85 year old women and men. These lisks were estimated using 
Kaplan-Meier product limit estimators of dementia f.oee survival and age-specific incidence as 
observed in a Dutch general population, the Rotterdam Study, 1990 - 1994. 
Age Period risk (%) Lifetime 
risk (%) 
5 yrs 10 yrs 15 yrs 20 yrs 25 yrs 30 yrs 35 yrs 40 yrs 
\Vomen 
55 0.0 0.6 1.5 3.1 9.9 17.5 26.3 31.0 32.6 
65 0.9 2.6 9.9 17.8 27.2 32.2 34.0 34.4 34.5 
75 8.1 16.9 27.3 32.7 34.8 35.3 35.4 35.4 
85 18.3 28.2 31.7 32.5 32.7 32.7 
Men 
55 0.7 l.l 1.5 3.2 7.7 12.7 15.0 15.9 15.9 
65 0.4 2.2 7.1 12.5 14.9 16.0 16.0 
75 6.4 13.4 16.6 18.0 18.0 
85 8.7 12.3 12.3 
Discussion 
For an average 2.1 years, we prospectively followed a large cohOlt from the general 
population, which was initially free of dementia. New cases of dementia were detected 
through in-person examination and a reporting system of possible new cases, for those 
who could not be re-examined. Age-specific dementia incidence rates and mOltality as 
observed in the study cohOlt, were used to estimate period risks of dementia, with 
competing risk of death taken into account. 
The strength of our study is threefold. First, high sensitivity and specificity of 
the in-person screening was ensured by a three phase comprehensive diagnostic 
work_up,14 which was similar at baseline and follow-up. Also, diagnoses were made by 
the same diagnostic panel. Second, through the repotts from the general practitioners 
and RIAGG we had a complete follow-up of all members of the cohott, including those 
who died, which reduces the potential bias due to selective secondary refusal or death. 
Age-specific incidence rates were quite similar for the in-person screened subjects and 
those whose medical files were studied after being reported with possible dementia, 
30 Incidence of dementia 
though we may have missed very mild cases in the latter group, p31ticularly in the 
highest age-bands. A third advantage of the study is its size, which resulted in stable 
age-, gender- and subtype-specific estimates of dementia incidence in the community, 
despite the relatively short duration of follow-up. 
We found the incidence of dementia for women to continuously increase with 
age, whereas there appeared to be a levelling off above age 85 for men. This pattern is 
consistent with reports from other studies."·15.16 A possible explanation is selective 
survival of men at lower risks for dementia. Also our fmding of a higher incidence of 
Alzheimer's disease in women and tendency to higher incidence of vascular dementia 
in men ~s in agreement with previous studies. 12,13,16 
Whereas incidence rates reflect the actual experience of a cohort, predictions of 
how much disease a population may expect inherently require risk estimates. For 
estimating risks of dementia, a disorder which is particularly frequent at oldest age, the 
considerable competing risk of death cannot be ignored. We approximated cumulative 
risks of dementia, taking competing mortality into account. The period risk of dementia 
should be interpreted as the probability of becoming demented within a cettain period. 
The lifetime risk, calculated at several ages, reflects the probability that a person of that 
age would at some time in his or her life suffer from dementia. This lifetime risk is 
determined by both individual risk and the popUlation's longevity. To our knowledge, 
only in the Framingham Study lifetime risks of dementia have been assessed 
previously.17 The Framingham estimates of dementia lifetime risks of 75 year old men 
(18.4%) and women (31.8%) were remarkably similar to ours (18.0% for men and 
35.4% for women). Although in our study cohort, the age-specific incidence rates of 
dementia were similar for men and women below age 85, the 30-year risk of 55 year 
old women to become demented was 1.4 times higher than the risk of men, which 
reflects the higher life expectancy of women. The combination of higher life 
expectancy and higher incidence in women than men over age 85 resulted in a much 
higher lifetime dementia risk of around I in 3 for women and I in 6 for men. Estimates 
of lifetime risks at different ages were quite similar. Having survived without dementia 
up to high age appears not to reduce a person's risk to develop dementia. 
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Chapfer 2.3 
Education and the risk of dementia 
Abstract 
We assessed the risk of dementia by educational level in a prospective population-based 
study. In the Rotterdam Study 6827 non-demented participants with known level of 
education were followed-up on average for 2.1 years. During this period 137 new cases 
of dementia occurred. Relative risks by educational. level were calculated with 
proportional hazards regression analysis, adjusting for age and, if applicable, sex. Low 
education. was associated with higher dementia risk in women but not in men, 
suggesting that the association is modified by gender. Our data suggest that cross-
sectional studies may overrate the association between education and risk of dementia. 
Introduction 
Many studies examined the relation between dementia and educational background.' 
Studies reporting an inverse association between education and dementia have been 
criticized for possible methodologic flaws like selection or diagnostic bias.2 Meanwhile, 
plausible hypotheses were fOlmulated to explain the relation: higher brain reserve 
capacity of educated persons could postpone the onset of dementia;3 educated elderly 
may get more brain stimulation ('use it or loose it,);3,4 and factors related to education, 
like lifestyle, occupational exposure, morbidity, and health care, may be responsible for 
the association with dementia.2,4 Most studies on the relation between education and 
dementia were cross-sectional.' We examined whether education influences the risk of 
dementia in a large prospective study. 
Methods 
STUDY DESIGN 
The Rotterdam Study is a community-based cohort study among 7983 persons aged 55 
years and over (response rate 78%),5 Baseline examinations took place from 1990 to 
1993. After 2 to 3 years, p8Iticipants were re-examined. Similar procedures were used 
for baseline and follow-up dementia screening,6 In brief, dementia was diagnosed 
through a three-step protocol including screening, cognitive testing, informant 
34 Chapter 2.3 
interviews, and a clinical dementia work-up. At baseline 6827 subjects with data on 
educational level were non-demented and thus at risk for incident dementia. Of subjects 
who died before follow-up (7.5%) or were not re-examined in person (12.4%) 
information was obtained from informants and general practitioners to complete follow-
up. Diagnoses were made according to CUlTent clinical criteria (DSM-III-R, NINCDS-
ADRDA, NlNDR-AIREN) by a panel that reviewed all existing infonnation. 
DATA ANALYSIS 
Educational level was grouped in three categories: (I) primary education or less; (2) 
lower vocational or intermediate general education; (3) intermediate vocational to 
university level. 7 Relative risk of dementia was assessed with a propOitional hazards 
model, adjusting for age (linear and squared) and gender. The highest level of 
education was used as reference. \Ve examined if the association was different for 
Alzheimer's disease and other dementias. Analyses were performed on all subjects and 
for men and women separately. 
Results 
In table I characteristics of the study population are summarized. After a mean 2.1 
years of follow-up 137 incident dementia patients had been diagnosed. The incidence 
rate was higher in women than men because of a different age distribution. Age-
specific incidence rates were almost similar in men and women. Table 2 shows that the 
lower educated had a non-significant increased risk of dementia when compared with 
the higher educated (relative risk: lA, 95% CI 0.9 to 2.1). In men we observed no 
difference in dementia risk by education. Low educatcd women were at significantly 
TABLE 1. Characteristics of the study population. 
Men Women All 
Number (% of total population) 2767 (40.5) 4060 (59.5) 6827 
Mean baseline age (SD) 68.2 (8.1) 70.0 (9.4) 69.2 (9.0) 
Primary education or less (%) 730 (26.4) 1871 (46.1) 2601 (38.1) 
Medium level education (%) 637 (23.0) 1203 (29.6) 1840 (27.0) 
Higher education (%) 1400 (50.6) 986 (24.3) 2386 (34.9) 
Incident dementia (11000 person-years) 39 (6.9) 98 (11.1) 137 (9.5) 
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TABLE 2. Adjusted relative risk and 95% confidence interval of incident dementia by level of 
education. 
Level of education 
Primary education or less 
Medium level education 
Higher education 
Trend 
• Relative risks adjusted for age 
Men· 
0.7 (0.3 to 1.5) 
1.0 (0.5 to 2.1) 
1 (reference) 
p ~ 0.390 
t Relative risks adjusted for age and gender 
Women· 
2.1 (1.1 to 3.9) 
1.6 (0.8 to 3.2) 
(reference) 
p~0.018 
1.4 (0.9 to 2.1) 
1.2 (0.7 to 1.9) 
(reference) 
p~0.147 
increased risk of dementia (2.1, 95% CI 1.1 to 3.9). Analyses by subtype of dementia 
did not reveal a major difference between Alzheimer's disease and other dementias. 
Discussion 
This prospective study has several advantages over others which examined the 
association between education and dementia. The study is population-based with a high 
response rate. We also pursued complete follow-up of all subjects at risk. Therefore, 
there is little room' for selection bias. As opposed to register-based studies we actively 
screened for dementia, which prevented bias by differences in health-care-utilisation. 
The study was prospective and we assessed educational level before onset of dementia, 
thereby minimising recall bias. 
Studies on the relation between education and dementia are potentially affected 
by diagnostic bias. I,4 In cross-sectional studies subjects with life-long low cognitive 
abilities may elToneously be diagnosed demented. This bias is unlikely in the present 
study as those subjects should have been diagnosed as prevalent cases and were thus 
not at risk of incident dementia. We cannot completely exclude that the screening tests 
are more sensitive to pick up cognitive deficits associated with early dementia in the 
lower than in the higher educated, which could have resulted in an underestimation of 
the risk of dementia in higher educated. 
We previously described the association between education and prevalent 
dementia.6 The age and sex adjusted odds ratio of low education and dementia, 
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obtained in this cross-sectional study (2.7, 95% CI 1.9 to 4.0), suggested a greater 
association with education than our present results. In the prevalence study however, we 
could not avoid all above biases. Disproportionately few higher educated dementia 
patients may have been included in the cross-sectional analyses. There is evidence that 
highly educated dementia patients have a shOlter survival than the lower educated 
because their dementia remains unrecognized untill a more progressed stage." The 
higher educated could thus be unden-epresented in prevalent case series but not be at 
lower risk of dementia. Cross-sectional studies, which mostly repOlted strong 
associations, I may have oven'ated the association of education with dementia risk. 
The present results suggest that the association between education and dementia 
may be modified by gender. A difference in the association by gender has not been 
described before. Re-analysis of our cross-sectional data affilmed also a difference 
(odds ratio in women, 4.7; in men, 1.8). This may be a direct effect of educational 
level; however, it may also be the result of interaction between education and gender 
with respect to dementia prognosis or risk factor profile.8 
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Chapter 3.1 
Cross-sectional association of diabetes mellitus and dementia 
Abstract 
Dementia and non-insulin-dependent diabetes mellitus are highly prevalent disorders in 
the elderly. Diabetes mellitus has repeatedly been repOlled to affect cognition, but its 
relation with dementia is uncellain. We therefore studied the association between 
diabetes and dementia in the Rotterdam Study, a large population-based study in the 
elderly. Of 6330 participants, aged 55 to 99 years old, complete infOlmation on diabetes 
and presence of dementia was available. Diabetes mellitus was diagnosed as use of anti-
diabetes medication or random or post-load selUm glucose over II mmoVI. Dementia 
was diagnosed through a stepped approach, including a sensitive screening of all 
p3llicipants and a comprehensive diagnostic work-up. 
Diabetes mellitus was present in 724 (11.4%) SUbjects. Of the 265 dementia 
patients 59 (22.3%) had diabetes. Multiple logistic regression analyses, adjusting for age 
and sex differences, revealed a positive association between diabetes and dementia 
(odds ratio: 1.3, 95% CI: 1.0-1.9). In particular, strong associations were found between 
dementia and diabetes treated with insulin (odds ratio: 3.2, 95% CI: 1.4-7.5). The 
relation was strongest with vascular dementia, but was also observed with Alzheimer's 
disease. These associations were independent of educational attainment, smoking, body 
mass index, atherosclerosis, blood pressure and antihype11ensive drug treatment, and 
and could not be explained by clinical cerebral infarctions. 
The results suggest that non-insulin-dependent diabetes mellitus is associated 
with dementia. Alzheimer's disease may be more frequent in elderly diabetes patients 
treated with insulin. 
Introdnction 
Non-insulin-dependent diabetes mellitus (NIDDM) is a well known risk factor for 
cardiovascul3l' disease and stroke. I•3 Apart from the obvious lesions caused by strokes, 
also subtle neurochemical, electrophysiologic and structural changes have been found in 
brains of patients with NIDDM.3.' Neuropsychologic test profiles of NIDDM patients, 
compared to those of healthy 01' hospital controls, showed decreased cognitive 
functions.6·9 Several authors suggested that, analogous to its association with cerebral 
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infarction, NIDDM is related to vascular dementia. IO•11 However, the extend to which 
NIDDM is associated with other dementia subtypes, in particular Alzheimer's disease 
(AD), is unclear. 12ol ' We examined the association between NIDDM and prevalent 
dementia in a large population based study. 
SUBJECTS 
The Rotterdam Study is a population-based prospective follow-up study in which 
several impOliant diseases of the elderly are investigated. 16 The study focuses on four 
groups of diseases: neurological, cardiovascular, locomotor and ophthalmologic 
diseases. All inhabitants of Ommoord, a suburb of Rotterdam, aged 55 years and older, 
including those living in institutions, were invited to paIiicipate in the study. Of the 
10275 eligible subjects, 7983 participated in the Rotterdam Study. Between ·1990 and 
1993 participants were extensively interviewed at their homes and exanlined at the 
research centre in order to collect baseline data and to ascertain their health status. 
Dementia status was missing in 455 (6%) subjects, mainly because they refused the 
cognitive screening test. Blood glucose measurements started in July 1990, after the 
pilot phase in which 544 randomly choosen participants had been examined. Of the 
7439 subjects who were examined since then, blood glucose measurements were absent 
in 821 (11%), mainly due to logistic or technical problems. In the present analyses 
6330 paIiicipants (85%), with complete information on dlUg use, blood glucose 
measurements and the presence of dementia were included. Dementia and diabetes 
assessments took place completely independent of each other without prior knowledge 
to the study physicians of which associations would later be tested .. 
EXAMINATIONS 
The prevalence of dementia was assessed using a three phase approachY With a brief 
cognitive test, the combined Mini Mental State Examination (MMSE)IS and Geriatric 
Mental State schedule (GMS-A, organic level),19 the population was screened for 
dementia. This test was administered by trained research assistants. Screen positive 
subjects (Mini Mental State Examination score below 26 or Geriatric Mental State score 
above 0) were subsequently examined by a physician with the Cambridge Examination 
for Mental Disorders of the Elderly diagnostic interview.2o PaIiicipants who were 
suspected of dementia after this interview underwent an extensive examination which 
included examinations by a neurologist, a neuropsychologist and brain magnetic 
resonance imaging. Based on all available information a diagnosis of dementia was then 
made according to DSM-IIl-R criteria,21 with a sUbdiagnosis of AD based on 
NINCDS-ADRDA criterian and of vascular dementia in accordance with NINDS-
AIREN criteria.'3 
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Current dlUg use was assessed during the initial home interview. Patiicipants 
were asked to show all medication they were using. Of institutionalised participants, 
medication was reported by the medical staff. From all patiicipants blood IVas drawn by 
venipuncture and allowed to coagulate for 30 minutes. Subjects without anti-diabetic 
medication subsequently received a glucose drink of 200 ml which contained 75 g of 
glucose. Two hours later a second blood sample was obtained. Random and post-load 
glucose levels were measured by the glucose hexokinase method. Diabetes mellitus was 
defmed as the use of anti-diabetic medication or at least one glucose value greater than 
11 mmolli. 
Level of education was assessed during the initial interview and grouped in four 
levels, from primary school only to college and higher. Smoking habits were assessed 
during interview and categorised as never, former or CutTent smoking. The body mass 
index was calculated by dividing weight through the square of height and expressed as 
kg/m2• Systolic blood pressure was measured with a random zero sphygmomanometer. 
The ankle-to-brachial index (the ratio of the systolic blood pressure measured at the 
ankle and the upper arm) was used as a measure of peripheral atherosclerosis: a ratio of 
0.9 or below was considered positive.24 Resting ECG's were analysed by the Modular 
ECG Analysis System (MEANS) computer program.2S This program contains modules 
for rhythm classification, contour analyses and Minnesota coding and was shown to 
give very accurate ECG diagnoses.26 The presence of coronary artery disease, was 
approximated by the program's diagnosis of probable or definite myocardial infarction, 
which was used as a second measure of atherosclerosis. A history of stroke was 
determined through interview or in dementia patients through informant interview, and 
verified with medical records. 
STATISTICAL ANALYSIS 
The association between NIDDM and dementia IVas examined by calculating odds 
ratios (OR) by multivariate logistic regression with dementia as the dependent, and 
NIDDM, age and sex as independent variables in the model. In all regression models 
age was treated as a continuous variable. To assess whether this relation was different 
across levels of severity of NIDDM, we performed subanalyses in which we compared 
patients without anti-diabetes medication, patients using oral anti-diabetes medication 
and patients treated with insulin, to non-diabetic subjects. In addition to age and sex, 
we included educational level, smoking, body mass index, atherosclerosis, systolic 
blood pressure level and antihypertensive dlUg treatment to the regression model in 
order to adjust for confounding by these variables. To examine whether the association 
could be explained by an increased stroke risk in diabetes patients, the analyses were 
repeated in subjects without stroke history. 
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Results 
Of the 6330 subjects in this study, 265 (4.2%) were diagnosed with dementia (table 1). 
In 194 the dementia was of the Alzheimer disease (AD) type (73%), 44 subjects had a 
vascular dementia (17%), and 27 had other dementias (10%). Of the AD patients 32 
(16%) had cerebrovascular disease, based on a history of stroke or cerebral magnetic 
resonance imaging findings, that was considered not directly etiologically related to the 
dementia. Ages ranged from 55 to 99 years old. Dementia prevalence increased sharply 
with age: from 0.3% in the age group of 55-64 to 30% in subjects of 85 and older. 
Since the older age groups had higher proportions of women, there were relatively 
more women with dementia. The prevalence of NlDDM also increased with age: from 
6% in the age group of 55-64 to 22% in subjects of 85 and older. NlDDM was 
diagnosed in 11 % of the non-demented participants and in 22% of the dementia 
patients. Among AD, vascular and other dementia patients, 21%, 30% and 19% had 
NIDDM, respectively. Of the NIDDM patients 34% was using oral medication and 10% 
got insulin treatment. These proportions were similar among the dementia patients. 
After adjustment for age and sex differences, dementia patients had a significantly 
higher serum glucose level, a lower body mass index and systolic blood pressure, more 
frequent history of stroke and a lower educational status than subjects without dementia. 
Table 2 shows the association between diabetes and dementia for the total 
population and for men and women separately. In women a significant association with 
dementia was observed (OR: 1.5, 95% CI: 1.0-2.2). However, NIDDM treated with 
insulin was strongly con'elated to dementia in both men and women (OR: 3.2, 95% CI: 
1.4-7.5, for both sexes combined). Additional adjustments for possible confounders did 
only marginally alter the associations. 
Both NIDDM and dementia patients had more often stroke histories than 
participants without diabetes or dementia. Excluding subjects with a history of stroke 
however, did not change the association between diabetes and dementia (OR: 1.3, 95% 
CI: 0.9-1.9 for overall NIDDM and OR: 3.0, 95% CI: 1.1-7.8 for NIDDM treated with 
insulin). 
In table 3 the associations between diabetes and dementia subtypes are given. 
The association of insulin treated NlDDM to dementia was observed for all subtypes, 
but was strongest for vascular dementia. Diabetes treated with oral medication was 
significantly associated with vascular dementia. Again additional adjustments for 
confounders resulted in essentially similar associations. 
TABLE 1. Characteristics of the total study population, of demented and non-demented subjects. 
Total Non~demented 
population subjects 
Population size 6330 6065 
Women (%) 59.4 58.9 
Age (years) • 69.3 (9.1) 68.7 (8.7) 
Random serum glucose (mmol/l) • 6.9 (2.7) 6.9 (2.6) 
NIDDM (%) 11.4 11.0 
no drug treatment (% of NIDDM) 55.9 56.1 
oral medication (% ofNIDDM) 33.7 33.8 
insulin treatment (% ofNIDD11) 10.4 10.1 
Only primary education or less (%) 24.2 22.6 
Ever smoking (%) 64.3 65.0 
Body mass index (kg/m') • 26.3 (3.7) 26.3 (3.7) 
Peripheral atherosclerosis (%) 18.4 17.1 
ECG myocardial infarction (%) 9.2 8.9 
Systolic blood pressure (mmHg) • 139.5 (22.6) 139.4 (22.5) 
Treated with antihypertensives (%) 1" 32.5 32.0 
Stroke history (%) 3.3 2.8 
• Mean (standard deviation), 
t including all beta-blocker and diuretic drug use, 
! Difference between non-demented and demented subjects adjusted for age and sex. 
NIDDM ::::: non-insulin-dependent diabetes mellitus; 95%CI = 95 % confidence interval. 
Demented 
subjects 
265 
71.3 
83.3 (7.8) 
7.9 (3.9) 
22.3 
54.2 
32.2 
13.6 
64.8 
47.2 
25.3 (3.9) 
47.8 
17.2 
141.5 (24.6) 
44.9 
15.5 
Adjusted difference' 
(95%CI) 
0.5 (0.1 - 0.8) 
3.2 (-0.4 - 7.8) 
20.2 (13.0 - 27.8) 
-4.8 (-12.5 - 2.3) 
-1.2 (-1.8 - -0.7) 
4.2 (-0.5 - 9.9) 
2.4 (-0.8 - 6.7) 
-7.6 (-10.6 - -4.7) 
-4.0 (-9.0 - 1.7) 
4.7 (2.3 - 8.2) 
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TABLE 2. Association of non-insulin-dependent diabetes mellitus (NIDDM) with dementia. 
Total Men Women 
Adjusted for age, sex 
NIDDM overall 1.3 (1.0 - 1.9) • 0.9 (0.5 - 1.8) 1.5 (1.0 - 2.2) 
no drug treatment 1.2 (0.8 - 1.9) 1.0 (0.4 - 2.2) 1.4 (0.8 - 2.3) 
oral medication 1.2 (0.7 - 2.1) 0.5 (0.1 - 2.2) 1.5 (0.8 - 2.6) 
insulin treatment 3.2 (1.4 - 7.5) 3.2 (0.7 - 16.0) 3.2 (1.2 - 8.7) 
Additional adjustments t 
NIDDM overall 1.2 (0.9 - 1.8) 0.7 (0.3 - 1.5) 1.5 (1.0 - 2.3) 
no drug treatment 1.2 (0.8 - 1.9) 0.8 (0.3 - 2.0) 1.4 (0.8 - 2.5) 
oral medication 1.0 (0.6 - 1.8) 0.3 (0.1 - 1.5) 1.3 (0.7 - 2.5) 
insulin treatment 2.6 (1.1 - 6.2) 2.1 (0.4 - 11.5) 2.8 (1.0 - 7.6) 
* Odds ratio, 95% confidence interval 
t Adjusted for education, smoking, body mass index, atherosclerosis, systolic blood pressure and 
antihypertensive drug treatment 
TABLE 3. Association between non-insulin-dependent diabetes mellitus (NIDD:M) and 
subtypes of dementia, ~djusted for age and sex. 
NIDDM overall 
no dmg treatment 
oral medication 
insulin treatment 
NIDDM overall 
no dmg treatmel)t 
oral medication 
insulin treatment 
Alzheimer's disease 
N ~ 194 
1.3 (0.9 - 1.9) • 
1.3 (0.8 - 2.0) 
1.3 (0.6 - 2.0) 
2.8 (1.0 - 8.0) 
AD without CVD 
N~ 162 
1.3 (0.9 - 2.0) 
1.3 (0.8 - 2.2) 
0.9 (0.5 - 2.0) 
3.5 (1.2 - 9.8) 
• Odds ratio, 95% confidence interval 
Vascular dementia 
N ~ 44 
2.1 (\.I - 4.0) 
1.l (0.4 - 3.2) 
3.2 (1.4 - 7.4) 
5.4 (1.2 - 23.8) 
AD with CVD 
N ~ 32 
1.1 (0.4 - 2.7) 
0.9 (0.3 - 3.1) 
1.6 (0.5 - 5.5) 
no cases 
AD = Alzheimer's disease; CVD = cerebrovascular disease 
Other dcmentias 
N ~ 27 
\.I (0.4 - 2.9) 
1.5 (0.5 - 4.4) 
no cases 
3.5 (0.4 - 27.0) 
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Discussion 
In this study we investigated the relation between non-insulin·dependent diabetes 
mellitus and dementia. NIDDM treated with insulin was strongly associated with 
dementia and this was independent of level of education, smoking, body mass index, 
presence of atherosclerosis, systolic blood pressure and antihypettensive medication. 
The association could not be explained by an increased prevalence of clinical strokes. 
The association was found with vascular dementia and Alzheimer's disease (AD). In 
vascular dementia the relation tended to be stronger with more severe NIDDM, whereas 
in AD an association was mainly found with NIDDM treated with insulin. 
Three possible biases need to be discussed. Firstly, we did not obtain a 100% 
response. We do know that non-responders were on average older than. the study 
pmticipants. Dementia patients more often had to be excluded due to incomplete 
diabetes or risk-factor information. This, however, would only invalidate our results if 
the relation between NIDDM and dementia was different among non-responders as 
compared to participants, which we consider unlikely. Secondly, because we studied the 
relation between diabetes and dementia cross-sectionally, bias could have OCCUlTed due 
to survival effects.'7 This could have resulted in an overestimation of the relation if the 
relative decrease in survival due to diabetes would be greater in nondemented than 
demented subjects or in an underestimation if the combination of NIDDM and dementia 
in a patient would interact and lead to increased mortality. If anything, we consider the 
latter more likely. Thirdly, subtyping dementia, even if based on generally accepted 
diagnostic criteria, remains difficult and some misclassification cannot be excluded. 
Furthennore, although the criteria for vascular dementia are appropriate for identifying 
multi-infarct dementia, they may fail to identify subjects in whom other vascular 
mechanisms played an important etiological role, and vascular factors may be involved 
in AD as weI1."·23.28.29 In the present study AD was associated with NIDDM, 
paIticularly diabetes treated with insulin, even after exclusion of patients with 
cerebrovascular disease from the AD group. 
The relation of NIDDM with dementia was similar between men and women 
only for NIDDM treated with insulin. In untreated and tablet treated NIDDM a relation 
with dementia also seemed present in women but not in men. We do not know if this is 
simply due to the low number of men with both NIDDM and dementia, resulting in an 
unstable odds ratio with wide confidence intervals or whether this reflects a greater 
inpact of NIDDM on women. The latter was suggested in a report from the 
Framingham Heart Study, in which relatively more cardiovascular disease was found in 
diabetic women than men.30 
Our results indicated that atherosclerosis had only limited influence on the 
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association between NIDDM and dementia. We cannot though completely exclude 
atherosclerosis as an etiologic factor. In order to investigate the relative contribution of 
strokes we investigated the association in a subgroup without history of stroke. Though 
the association was also found in subjects without a histOlY of stroke it remains possible 
that silent infarctions due to NIDDM pathology may underly the excess of dementia in 
diabetic subjects. 
Our finding of an increased prevalence of vascular dementia in diabetes patients 
is in line with results from a study in which 175 multi-infarct dementia patients were 
compared with 125 age-matched neurologically normal controls.31 Diabetes was 2.8 
times more prevalent in cases than in controls. And in a recent Japanese community 
based study on the incidence of dementia, it was shown that NIDDM patients had an 
increased risk to develop vascular dementia (age adjusted relative risk: 2.8).15 
Furthermore, Tatemichi et al. showed that in stroke patients, diabetes was associated 
with a higher rate of dementia 3 months after the stroke (OR: 2.6).32 
Our findings of a relation between insulin treated NIDDM and AD contrasts 
with results of studies which suggested that diabetes mellitus is less frequent among AD 
patients than controls. 12-14 These studies were relatively small, used selected clinical 
AD cases, and geriatric clinic patients,I2 vascular dementia13 or population controls,I4 
Our results are in accordance with the Japanese Hisayama Study which repOlted that 
NIDDM patients had an increased risk to develop AD after 7 years of follow-up 
(relative risk: 2.2, 95% CI: I.O-4.9)Y 
The relation between NIDDM and AD may be explained by diabetic 
vasculopathy and its sequelae. The common coincidence of AD with cerebral 
infarctions and subcortical white maUer lesions ll •33.34 suggest that vascular factors may 
be important in AD. However, other and more direct mechanisms could be involved. 
Recently, increased glycation of proteins and advanced glycation end products (AGE), 
which may be involved in the etiology of diabetes complications, were found in plaques 
and tangles of AD patients.35.36 AGE epitopes were even detected in the earliest states 
of Alzheimer brain lesions and do promote known plaque and tangle properties. 
Progressive glycation augments the deposition of proteins by crosslinking, it induces 
macrophages to secrete acute phase reactants, thereby stimulating inunune-cell response 
and it might contribute to nerve-cell death by the formation of /i'ee radicals?7,J8 
Altematively, NIDDM effects on neurotransmitter metabolism could contribute to AD. 
In chronic diabetes, a considerable decline in the blood-brain balTier transport of 
choline, a precursor of acetylcholine, is found.3 Changes in brain glucose utilisation or 
insulin induced hypoglycemias might contribute to.a reduced acetylcholine synthesis.5,39 
Blocking of acetylcholine muscarinic receptors is known to dislUpt higher cognitive 
functions and AD severity is correlated to the loss of brain cholinergic activity.38,39 
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Finally, we found that the cOlTelation between NIDDM and AD was strongest in 
NIDDM patients treated with insulin. Most likely these patients had a more serious and 
long-standing diabetes. It is however conceivable that exogenous insulin itself or 
hypoglycemias which frequently complicate insulin therapy40 increase the risk of 
dementia and AD. A direct correlation has been reported between increased endogenous 
insulin level and impaired cognitive function.4 ! 
In conclusion, we found that NIDDM, particularly when treated with insulin, is 
associated with dementia, both vascular dementia and AD. It is as yet unclear which 
pathophysiologic mechanisms could explain this association. 
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Chapter 3.2 
Diabetes mellitus and the risk of dementia 
Abstract 
Objective: To determine whether diabetes mellitus and measures of glucose 
metabolism are associated with increased risk of dementia and Alzheimer's disease. 
Design: Population-based prospective cohort study. 
Setting: A district of Rotterdam, the Netherlands. 
Participants: 6370 non-demented residents, aged 55 years and older. 
Measurements: Non-insulin-dependent diabetes mellitus was diagnosed at baseline if 
random or two hour post-load serum glucose was over 11 mmolll or if antidiabetes 
medication was used. At baseline, also serum fructosamine and post-load insulin levels 
were assessed. Incident dementia was diagnosed, after a mean 2.1 years of follow-up, 
using a three step approach, including a sensitive screening and comprehensive 
diagnostic work-up. Of subjects who could not be re-examined, medical files were 
studied to diagnose dementia. Relative risks were estimated with proportional hazard 
regression, adjusting for age and sex. 
Results: At baseline 692 (10.9%) participants had diabetes. During the follow-up 
period 126 subjects became demented, of whom 89 had Alzheimer's disease. The 
relative risk of diabetes patients to develop dementia was 1.9 (95% CI 1.3 to 2.8), and 
to develop Alzheimer's disease 1.9 (95% CI 1.2 to 3.1). Diabetes patients treated with 
insulin were at highest risk of dementia (relative risk 4.3, 95% CI 1.7 to 10.5). Levels 
of serum glucose, fructosamine, post-load insulin, and insulin resistance were not 
associated with increased risk of dementia. In this population the attributable risk of 
diabetes mellitus for dementia was 8.8%. 
Conclusions: Diabetes mellitus ahnost doubled the risk of dementia. Diabetes mellitus 
could underlie a substantial proportion of all dementia. 
Introduction 
Both dementia and non-insulin-dependent diabetes mellitus (NIDDM) are frequent 
disorders in elderly people and major causes of disability. Little is known about their 
relationship. As NIDDM is a risk factor for stroke,I,2 it is supposed to be linked with 
vascular (mainly multi-infarct) dementia.3,4 Some studies found higher than expected 
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prevalence rates of diabetes in patients with multi-infarct dementia5.? and persons who 
had suffered from a stroke appeared at greater risk of subsequent dementia if they had 
diabetes.8 Previous case-control studies reported decreased rates of diabetes mellitus in 
Alzheimer patients.6,7,9-11 However, we found a positive association in a population-
based prevalence study.12 Recently, advanced glycation end-products (AGE) and 
increased AGE receptor expression were discovered in brains of patients with 
Alzheimer's disease. 13,14 As AGE's are thought to be involved in NJDDM 
complications l5 these findings W3lTant further investigation into the relation of diabetes 
mellitus with dementia and Alzheimer's disease. 
We studied the risk of dementia by diabetes in a population-based prospective 
cohOlt study. In addition we assessed the association between measures of glucose 
metabolism and incident dementia. 
Methods 
STUDY POPULATION 
The Rotterdam Study is a community-based prospective cohOit study in which chronic 
disorders of the elderly are investigated. 16 The study was approved by the Medical 
Ethics Committee of Erasmus University. Patiicipants gave written informed consent 
and permission to retrieve infOlmation from treating physicians. 
The study was c3lTied out in a suburb of the city of Rotterdam, the Netherlands. 
Baseline examinations were performed from 1990 to mid 1993. The eligible population 
(n~10275) consisted of all persons aged 55 years and older living in this suburb, and 
included people living in institutions. Of those, 7983 took part in the baseline 
examinations of the study (response rate 78%). During baseline 7528 (94%) were 
screened and examined for dementia:7 Exclusion of prevalent dementia patients 
resulted in a cohort of 7046 subjects at risk for dementia. Diabetes examinations were 
not performed during the pilot phase of the baseline study (n~33) and measurements 
were incomplete due to logistic reasons in 243 subjects. This left 6370 persons to be 
included in the present prospective study. Follow-up examinations took place from 
September 1993 to the end of 1994. During this second round of the study 5232 (82%) 
participants were re-examined for dementia; 330 (5%) had died before follow-up and 
808 (13%) refused examinations or were too ill. Of the 1138 subjects who were not rc-
examined information on dementia starns was obtained through general practitioners 
and medical records. 
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DEMENTIA CASE-FINDING 
Both at baseline and follow-up dementia was diagnosed with a three step protocol, 
consisting of a brief cognitive screening (Mini Mental State Examination!S and the 
Geriatric Mental State schedule,!9 organic level) and an extensive diagnostic work-upY 
In addition to the follow-up examinations, the study cohort was monitored 
through linkage with the general practitioner's automated medical record system and 
close cooperation with the regional institute for outpatient mental health care (RIAGG) 
which is responsible for dementia-care-facilities and nursing home indications. Of 
interval cases reported with memory problems or dementia, and of subjects who could 
not be re-examined, information was obtained from medical files. Through this 
surveillance system we were able to obtain a complete follow-up of the population at 
risk. 
Both baseline and follow-up diagnoses of dementia were made by a panel 
consisting of a neurologist, neuro-psychologist, and the study physician, who reviewed 
all existing information. A diagnosis of Alzheimer's disease was based on National 
Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's 
Disease and Related Disorders Association criteria.>o Vascular dementia was diagnosed 
in accordance with National Institute of Neurological Disorders and Stroke and 
Association Intel'natiollale pour fa Recherche et I'Enseigllement en Neurosciences 
criteria'>! As proposed in the latter criteria we recognised a subgroup of Alzheimer's 
disease with cerebrovascular disease. For other dementias, the criteria from the 
Diagnostic and Statistical Manual of mental disorders (3rd ed., revised) were used.22 
DIABETES AND OTHER BASELINE MEASUREMENTS 
During the initial home interview current dlUg use was assessed by asking pmiicipants 
to show all medication they were using. Of institutionalised participants, medication 
was reported by the medical staff. Blood was drawn by venipuncture to assess non-
fasting glucose and flUctosamine levels. Participants who did not use antidiabetes 
medication received a glucose drink of 75 grams in 200 ml water. Two hours later a 
second blood sample was obtained to measure post-load selUm glucose and insulin (by 
radioimmunoassay, Medgenix diagnostics, BlUssels, Belgium). Diabetes mellitus was 
defined according to WHO criteria for epidemiologic studies of diabetes as the use of 
antidiabetes medication or at least one glucose value greater than II 1010011[.23 As a 
measure of insulin resistance we used the ratio of post-load insulin over post-load 
glucose. which provides a good estimate in subjects without diabetes mellitus.2• 
The following variables were measured and tested as possible confounders or 
intennediates. Level of education was assessed during the initial interview and for the 
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analyses dichotomised in less than 7 years of education or more. Weight and height 
(measured with indoor clothing and no shoes) were used to calculate body mass index, 
expressed in kg/m2. The ratio between waist circumference (measured midway between 
lower rib and iliac crest) and hip circumference (at the greater trochanter) was used as 
measure of body fat distribution. Smoking habits at baseline were categorised as never, 
past, and current smoking. Alcohol consumption was assessed as part of a semi-
quantitative food frequency questionnaire and expressed as the intake in grams of pure 
alcohol per day. Systolic blood pressure was measured in supine position with a random 
zero sphygmomanometer. Hypertension was defined as a systolic blood 'pressure of 160 
or above, a diastolic blood pressure of 95 or above, or the use of antihypertensive 
drugs. Ankle-ta-brachial index, used as a measure of peripheral atheroscierosis,25 was 
calculated as the ratio of the systolic blood pressure measured at the ankle over that 
measured at the upper arm. The presence of atrial fibrillation was assessed on resting 
ECG by computer software.26 A computer diagnosis of probable or definite myocardial 
infarction was used as another measure of atherosclerosis. A history of stroke was 
assessed during the baseline interview and verified with medical records by a 
neurologist. 
DATA ANALYSIS 
Means and prop0l1ions of baseline characteristics were compared for subjects with and 
without diabetes mellitus. Also, means of glucose metabolism measures at baseline were 
compared for subjects with incident dementia and those who remained non-demerited. 
Age and sex adjusted differences were calculated with logistic regression analyses for 
dichotomous variables and with linear regression for continuous variables. 
Relative risks of dementia by diabetes were calculated with a Cox prop0l1ional 
hazard regression model, in which the covariates describe the risk of dementia as a 
function of follow-up time. To adjust for age, both linear and squared age were entered 
in the models. Gender was added to the model in analyses which included men and 
women. We examined if gender or age modified the relation by calculating relative 
risks for men and women separately, and in strata of age (below 75, 75 to 85, and of 
85 years and older). To check if associations could be attributed to confounding, 
analyses were repeated with possible confounders added to the models. Similarly, we 
checked if the association remained, independent of possible intermediates. 
We assessed which proportion of incident dementia was attributable to diabetes 
or to factors associated with diabetes as described by Levin.>? This population 
attributable risk (PAR) was calculated using the adjusted relative risk (RR), the 
. population fraction with diabetes (PF), and the formula: 
PAR = [(RR - I)PF] / [1 + (RR - I)PF]. 
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Finally, we assessed the influence of random seIUm glucose, fIUctosamine, post 
load insulin, and insulin resistance on the risk for dementia. This was done by adding 
Ihese glucose metabolism measures both as continuous or as categorical (quintiles) 
variables to the propOltional hazard regression model. We examined whether Ihe 
influence of these measures on dementia risk was different for subjecls without or with 
diabetes mellitus. 
Results 
At baseline, of the 6370 subjects in Ihis study, 692 (10.9%) had diabetes mellitus, of 
whom 390 (56.4%) used no antidiabetes medication or were newly diagnosed, 232 
(33.5%) used oral medication, and 70 (10.1%) were treated with insulin. Among those 
using insulin therapy, there were no cases with insulin-dependent diabetes mellitus.28 
Diabetes prevalence increased wilh age. After age-adjustment there was no difference in 
diabetes rates between men and women. Of the possible confounders or intermediates 
only the rates of low education and atrial fibrillation were not significantly different 
between subjects with and without diabetes mellitus (table 1). 
TABLE 1. Baseline characteristics and selected variables of study participants, with and 
without non-insulin dependent diabetes mellitus (NIDDM) .• 
NIDDM No NlDDM Adjusted difference p-
(n ~ 692) (n ~ 5678) (95% el) t value t 
Age (years) 72.6 (8.8) 68.4 (8.6) 
Women (%) 60.0 59.1 
Less than 7 years of education (%) 27.2 22.4 -0.8 (-3.9 to 2.6) 0.63 
Body mass index (kg/m2) 26.8 (4.2) 26.2 (3.7) 0.6 (0.2 to 0.9) < 0.001 
Waist to hip ratio 0.93 (0.Q9) 0.90 (0.09) 0.02 (0.02 to 0.03) < 0.001 
Current smoking (%) 23.1 22.9 3.6 (0.0 to 7.6) 0.05 
Alcohol intake (g/day) II.! (18.6) 10.3 (14.9) 1.3 (0.0 to 2.6) 0.05 
Systolic blood pressure (mmHg) 147.9 (24.2) 138.3 (22.0) 6.9 (5.1 to 8.6) < 0.001 
Hypertension (%) 50.8 31.8 14.6 (3.7 to 26.3) < 0.001 
Ankle to brachial blood pressure index 0_97 (0.3) 1.07 (0.2) -0.07 (-0.09 to -0.05) < 0.001 
ECG myocardial infarction (%) 13.5 8.3 3.5 (1.1 to 6.3) 0.002 
Atrial fibrillation (%) 4.0 2.3 0.5 (-0.5 to 2.0) 0.33 
Stroke history (%) 5.9 2.4 2.2 (0.8 to 4.1) < 0.001 
• Values are proportions or means (SD) 
t Adjusted for age and gender. 
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TABLE 2. Baseline glucose metabolism and dementia status after 2.1 years of follow-up. ~ 
Dementia 
at follow-up 
(11 ~ 126) 
Age (years) 80.6 (7.7) 
\Vomen (%) 73.8 
Random sennll glucose (1111110111) 7.7 (3.0) 
Fmctosamine (l.unoUt) 310.2 (68.8) 
Post load insulin (mUll) t 77.8 (61.0) 
Insulin resistance (mU/mlllol) t 10.3 (6.9) 
Diabetes mellitus (%) 27.0 
• Values are proportions or means (SD) 
t Adjusted for age and gender. 
No dementia 
at follow-up 
(11 ~ 6244) 
68.6 (8.6) 
58.9 
6.9 (2.6) 
309.0 (51.3) 
61.6 (52.0) 
8.8 (6.4) 
10.5 
t Not assessed in subjects who used antidiabetes medication. 
Adjusted difference p-
(95% CI) t value t 
0.1 (-0.2 to 0.5) 0.43 
-5.0 (-15.1 to 5.1) 0.33 
4.7 (-6.0 to 15.4) 0.39 
0.6 (-0.6 to 2.0) 0.35 
7.7 (1.9 to 15.0) 0.005 
During a mean 2.1 years of follow-up, 126 (2.0%) participants became 
demented. Of those 89 (70.6%) were diagnosed as Alzheimer's disease (76 without and 
13 with cerebrovascular disease), 18 (14.3%) had a vascular dementia, and 19 (15.1%) 
another type of dementia. Dementia patients were significantly older than those who 
were non-demented. There was no age adjusted difference in dementia risk by gender. 
The prevalence of diabetes was 10.5% in those who did not develop dementia, and 
27.0% in subjects who developed dementia (table 2). This difference was significant, 
also after adjustment for age and sex. Incident dementia patients did not differ 
significantly from non-demented pat1icipants with respect to other measures of glucose 
metabolism (table 2). 
NIDDM almost doubled the risk of dementia (age and sex adjusted relative risk 
1.9, 95% CI 1.3 to 2.8, table 3), similarly for men (1.8, 95% CI 0.8 to 4.1) and women 
(1.9, 95% CI 1.2 to 3.0). When analyzed in strata of age no clear modification in 
diabetes related dementia risk was observed: For those below 75, 75 to 84, and of 85 
years and older relative risks were 2.0, 2.2, and lA, respectively. The relative risk did 
not differ between those examined in pe~'Son and the group in whom a diagnosis was 
made after reviewing medical files. The risk of incident dementia was clearly modified 
by type of treatment (table 3), with the lowest relative risk in diabetes patients not 
using antidiabetes medication (1.3, 95% CI 0.7 to 2.3) and the highest relative risk 
among those treated with insulin (4.3, 95% CI 1.7 to 10.5). Additional adjustment for 
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TABLE 3. Adjusted relative risk for dementia of non-insulin dependent diabetes mellitus and 
of three treatment categories of diabetes. Subjects without diabetes mellitus served as 
reference. ~ 
All diabetes mellitus 
no drug treatment 
oral medication 
insulin treatment 
Total population 
Relative Risk 
(95% el) 
1.9 (1.3 to 2.8) 
1.3 (0.7 to 2.3) 
2.4 (1.4 to 4.1) 
4.3 (1.7 to 10.5) 
Men 
Relative Risk 
(95% eI) 
1.8 (0.8 to 4.1) 
1.4 (0.5 to 4.0) 
2.2 (0.7 to 7.4) 
3.9 (0.5 to 29.5) 
• Adjusted for age and gender (total population) or age (men, women). 
Women 
Relative Risk 
(95% eI) 
1.9 (1.2 to 3.0) 
1.3 (0.7 to 2.6) 
2.4 (1.3 to 4.4) 
4.3 (1.6 to 11.8) 
TABLE 4. Relative risk for dementia by diabetes mellitus with, in addition to age and sex, 
adjustment fol' possible confounders or intermediates. 
Confounder or intemlediate 
Low education 
Body mass index 
Waist to hip ratio 
Smoking 
Alcohol intake 
Systolic blood pressure 
Hypertension 
Ankle to brachial blood pressure index 
ECG myocardial infarction 
Atrial fibrillation 
Stroke history 
Education, body mass index, waist hip ratio, smoking, and alcohol intake 
Systolic blood pressure, hypertension, ankle to brachial index, 
ECG myocardial infarction, atrial fibrillation, and stroke history 
Relative Risk (95% eI) 
1.8 (1.2 to 2.7) 
1.9 (1.3 to 2.8) 
1.9 (1.2 to 2.8) 
1.9 (1.3 102.8) 
1.7 (1.2 to 2.6) 
1.9 (1.3 102.9) 
2.0 (1.3 102.9) 
1.8 (1.2 to 2.7) 
1.8 (1.2102.7) 
1.8 (1.2 to 2.7) 
1.9 (1.3 to 2.8) 
1.7 (I.l to 2.5) 
1.8 (1.2 10 2.7) 
56 Chapter 3.2 
TABLE S. Age and gender adjusted relative risk for 
dementia subtypes of diabetes mellitus. Subjects without 
diabetes mellitus served as reference. 
Dementia subtype 
Total Alzheimer's disease 
without cerebrovascular disease 
with cerebrovascular disease 
Vascular dementia 
Other dementias 
Relative Risk (95% GI) 
1.9 (1.2 to 3.1) 
1.8 (1.1 to 3.0) 
3.0 (1.0 to 9.3) 
2.0 (0.7 to 5.6) 
1.6 (0.5 to 5.0) 
possible confounders or 
intermediates hardly 
influenced these results 
(table 4). Diabetes 
increased the risk of all 
types of dementia, 
including Alzheimer's 
disease (table 5). 
Additional adjustments 
for possible confounders 
again did not result in 
substantial changes of 
the estimates. 
In this population, ihe fraction of incident dementia attributable to diabetes 
mellitus was 8.8%. This population attributable liaction was 8.1% in men and 9.2% in 
women. 
We found no significant influence on dementia risk by semm glucose, 
fmctosamine, post load insulin, and insulin resistance (table 6), neither did we detect 
significant relative risks among subjects with values in the highest or lowest as 
compared to the median quintile of these glucose metabolism markers. 
TABLE 6. Age and gender adjusted influence on the risk for dementia of glucose metabolism 
measures, assessed for the total population, and for subjects without and with diabetes 
mellitus. The relative risk for dementia is given per standard deviation increase of value. * 
Total population Without diabetes With diabetes 
Relative Risk Relative Risk Relative Risk 
(95% el) (95% GI) (95% GI) 
Random sennll glucose 1.07 (0.92 to 1.24) 0.77 (0.51 to 1.16) 1.00 (0.81 to 1.25) 
Fructosamine 0.95 (0.79 to 1.14) 0.79 (0.62 to 1.02) 0.95 (0.72 to 1.25) 
Post load insulin t 1.04 (0.89 to 1.21) 1.08 (0.91 to 1.27) 0.87 (0.58 to 1.31) 
Insulin resistance t 1.04 (0.89 to 1.22) 1.07 (0.92 to 1.25) 0.89 (0.52 to 1.52) 
• One standard deviation (assessed in the total population) of random serum glucose: 2.6 InllloUI; 
fructosamine: 51.8 IHnoUI; post load insulin: 52.2 mUll; and insulin resistance: 6.4 mU/mmol. 
t Insulin and insulin resistance were not assessed in subjects who used antidiabetes medication. 
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Discussion 
In this large prospective study of dementia, subjects with NIDDM were at significantly 
increased risk of dementia, in particular if they were treated with insulin. NIDDM 
increased the risk of all types of dementia including Alzheimer's disease. Baseline 
serum glucose level, fructosamine, post-load insulin, and insulin resistance, did not 
influence the risk of dementia. These results confi.med our previous cross-sectional 
findings of an association of NIDDM with dementia and Alzheimer's disease. '2 Based 
on the results in this study we estimated that 8.8% of all dementia in the population 
could be attributable to NIDDM. 
Major advantages of the Rotterdam Study to investigate risk factors of dementia 
are the size of the study, the longitudinal and population-based design, and the fact that 
exposure and disease status were defined by thorough in-person examination. Diabetes 
status was assessed before onset of dementia which minimised asce.1ainment bias. 
Selection bias was minimised because the study was population-based and because 
follow-up of the population at risk of dementia was complete. 
A limitation of the present study is that brain imaging could not be obtained of 
all dementia patients and we may have underestimated the amount of cerebrovascular 
pathology of the demented subjects. We, however, consider it unlikely that the relation 
between diabetes and Alzheimer's disease is due to misclassification. The clinical 
Alzheimer's disease criteria that we used proved to be reliable.29 Compared to the 
results shown in table 5, NIDDM patients had a similar increased risk of Alzheimer's 
disease when we restricted our analyses to patients who had undergone brain imaging. 
Previous cross-sectional studies have shown positive associations of diabetes 
with vascular dementia, but a negative (inverse) relation with Alzheimer's disease.6,7,9-
II These studies were based on selected patients and controls. The presence of diabetes 
was assessed from medical records and not actually screened for. Furthermore, in these 
studies, patients with indicators of vascular or cerebrovascular disease were more or 
less rigorously excluded fi'om the Alzheimer group, thereby eliminating the possibility 
to study these factors in relation to Alzheimer's disease. Only two prior longitudinal 
studies on the risk for dementia by NIDDM have been published. A recent historical 
cohort study (Rochester, MN, USA) found among diabetes patients an increased risk of 
dementia (relative risk 1.7, 95% CI 1.3 to 2.1) and Alzheimer's disease (more 
pronounced in men (2.3, 95% CI 1.6 to 3.3) than women (1.4, 95% CI 0.9 to 2.0)).30 
Since this study was retrospective and register-based, disease asce.1airunent may have 
been selective and incomplete. A prospective population-based study (Hisayama, Japan), 
reported an increased risk among NIDDM patients of both Alzheimer's disease (relative 
risk 2.2, 95% ClI.O to 4.9) and vascular dementia (2.8, 95% CI 2.6 to 3.0).31 This 
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study among 828 elderly with a follow-up of seven years, pursued complete 
ascertaimnent of incident dementia. The results of these studies are in line with our 
findings. 
The relation between diabetes mellitus and dementia could either be explained 
through vascular disease or by non-vascular side-effects of diabetes. Diabetes mellitus is 
notorious for micro- and macrovascular complications.32 It is a well-known risk factor 
for strokes,I,2 which, if they accumulate or strike vital brain segments may cause 
dementia. 21 ,33 An increased risk of vascular (or multi-infarct) dementia by diabetes is to 
be expected. In case of Alzheimer's disease vascular mechanisms are less obvious. We 
cannot entirely exclude the possibility that we misdiagnosed some subjects with 
dementia due to vascular causes as Alzheimer's disease. However, the notion of 
vascular involvement in the pathogenesis of Alzheimer's disease is growing.21 ,34,35 
Also, small silent cerebral infarcts may have uncovered imminent Alzheimer's disease. 
The strong relative risk of Alzheimer's disease with cerebrovascular disease suggest 
vascular disease is often involved in diabetes-related dementia, 
There are several arguments to consider other than vascular factors as a cause of 
dementia in diabetes patients. The limited effect of adjustment for vascular risk 
indicators suggests a non-vascular pathway. Moreover, previous studies have reported 
non-vascular functional and stmctural changes in the central nervous system of diabetes 
patients,36.38 And NIDDM patients without clinical cerebrovascular disease 39.4Iwere 
found to perform significantly poorer on cognitive tests than healthy. controls. Recently, 
advanced glycation end-products (AGE), which are the result of nonenzymatic 
glycosylation of proteins,42 were found in plaques and tangles of Alzheimer brains, 
even in early stages of disease. I3 Excessive AGE formation by chronic hyperglycaemia 
may playa role in long-term diabetic complications." In brains of Alzheimer patients 
the receptor for AGE appears overexpressed,I4 and this receptor is activated by p-
Amyloid which is involved in Alzheimer pathology, If activated, oxidant stress is 
generated and cellular functions may disrupt.43,34 Likewise, diabetes-induced AGE's 
could cause brain dysfunction. 
Direct or indirect effects of insulin could contribute to the risk of dementia. In 
both this and our previous study we found that the highest risk was found for subjects 
on insulin treatment, suggesting that the risk is related to severity of NIDDM, 
Hypoglycaemic episodes frequently complicate insulin treatment,44 and contr3lY to 
hyperglycaemia, hypoglycaemia can cause irreversible brain damage.36,38 It cannot be 
excluded though that insulin itself may harm brain function. Though we did not find a 
relation of semm post-load insulin with dementia, high insulin levels have been 
associated with decreased cognition.45 
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We reported an increased risk of dementia in patients with diabetes mellitus. 
Non-insulin-dependent diabetes mellitus is a common disease in the elderly. For such 
common disorder, a 1.9 times increased risk of dementia as we found, implicates that a 
considerable proportion (8.8%) of all dementia could be attributed to diabetes. This 
high population attributable fraction ranges diabetes mellitus among the most important 
risk factors of dementia and Alzheimer's disease. 
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Chapter 4.1 
Atherosclerosis, apolipoprotein E, and the prevalence of 
dementia and Alzheimer's disease in a population based 
study 
Abstract 
63 
Background: Vascular disorders have been implicated in dementia, but whether 
atherosclerosis is related to the most frequent type of dementia, Alzheimer's disease, is 
not known. The apolipoprotein-E genotype has been associated with Alzheimer's 
disease, and we postulated that it plays a part, together with atherosclerosis, in the 
aetiology of Alzheimer's disease. We investigated the frequency of dementia and its 
subtypes in relation to atherosclerosis and apolipoprotein E. 
Methods: We did a population-based study of 284 dementia patients, 207 of whom had 
Alzheimer's disease, and 1698 individuals who were not demented. Indicators of 
atherosclerosis included wall-thickness and plaques of the carotid arteries, as assessed 
by ultrasonography, and systolic blood pressure ankle-to-brachial index, as a measure of 
generalized atherosclerosis. From these indicators a score of atherosclerosis ranging 
from 0 (no atherosclerosis) to 3 (severe atherosclerosis), was consttucted. 
Apolipoprotein-E polymorph isms were assessed in 246 patients and in 928 reference 
subjects. 
Findings: All indicators of atherosclerosis were associated with dementia (odds ratios 
ranging from 1.3 to 1.9), and its major subtypes, Alzheimer's disease (odds ratios 1.3 to 
1.8) and vascular dementia (odds ratios 1.9 to 3.2). The prevalence of all dementia, 
Alzheimer's disease and vascular dementia, increased with the degree of atherosclerosis. 
The odds ratio for Alzheimer's disease in those with severe atherosclerosis was 3.0 
(95% confidence interval 1.5-6.0; p ~ 0.001) as compared to those without 
atherosclerosis. In subjects with the apolipoprotein-E E4 genotype and an atherosclerosis 
score of 2 or 3 the odds ratio for all dementia was 4.5 (95% confidence interval 2.0-
10.1; P < 0.001). For Alzheimer's disease this odds ratio was 3.9 (1.6-9.6; P ~ 0.002), 
and for vascular dementia it was 19.8 (4.1-95.0; p < 0.001). 
/ntelpretation: These fmdings suggest that dementia, and its two major subtypes, 
Alzheimer's disease and vascular dementia, is associated with atherosclerosis. This 
study also suggests an interaction between apolipoprotein E and atherosclerosis in the 
aetiology of Alzheimer's disease. 
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Introduction 
Dementia is emerging as a mqjor health problem. I It is an imp0l1ant cause of disability, 
in p3l1icular in the elderly. The most important subtype of dementia is Alzheimer's 
disease, which accounts for at least half of all dementia cases.2 The causes of dementia 
and Alzheimer's disease are largely unknown, although recently important progress has 
been made in uncovering genetic factors that playa part in the aetiology of Alzheimer's 
disease. In particular, an association has been rep0l1ed of the apolipoprotein-E 84 allele 
with Alzheimer's disease.3•5 Atherosclerosis has been implicated in dementia since long, 
but except for a relatively small group of patients labelled as vascular dementia, no 
evidence for a role of atherosclerosis in dementia at large and Alzheimer's disease in 
particular, has been presented.6 The recently available non-invasive techniques to assess 
atherosclerosis provide the oppOltunity to study atherosclerosis and its putative sequelae 
in large populations. 
We report here a population-based cross-sectional study of atherosclerosis, the 
apolipoprotein-E genotype, and the prevalence of dementia and its subtypes in 284 
dementia patients and 1698 non-demented reference subjects. 
Patients and methods 
STUDY POPULATION 
This study was carried out as p3l1 of the Rotterdam Study, a single-centre prospective 
follow-up study for which all residents aged 55 years or over of the sublll'b of 
Ommoord in Rotterdam, the Netherlands were invited. The study has been approved by 
the Medical Ethics Committee of Erasmus University, and written informed consent has 
been obtained from all p3l1icipants. The objective of the study is to investigate 
determinants of chronic and disabling cardia-vascular, neura-degenerative, locomotor 
and ophthalmologic diseases, as described in detail elsewhere.7 Independently living 
pal1icipants were interviewed at home and subsequently clinically examined dlll'ing two 
visits at a research centre. For institutionalized persons the examinations were 
perfOlmed in their institute. The base-line examination of the Rotterdam Study, on 
which the present report is based, was conducted between March 1990 and July 1993. 
Of the 10275 eligible subjects, 7983 pm1icipated (78%), ranging in age from 55 to 106 
years. Of those who p3l1icipated, 7528 (94%) undenvent an extensive screening for 
dementia, and infonnation on cardiovascular risk factors, indicators for atherosclerosis 
and apolipoprotein-E genotype was obtained. The other 455 subjects where lost through 
refusal of the cognitive examination or death. Indicators for atherosclerosis were 
compared between 284 dementia patients and 1698 non-demented reference subjects. 
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DEMENTIA CASES 
Dementia was assessed by a three phase approach.s Firstly, all participants were 
screened with a brief cognitive test. Secondly, screen-positive subjects underwent 
additional cognitive and neurological testing. Thirdly, those whose results suggested a 
possibility of dementia were either subjected to a detailed examination or had their 
medical records used to confirm the diagnosis and establish the type of dementia. 
The brief cognitive test for dementia in the first phase comprised a combined 
Mini-Mental State Examination (MMSE)9 and Geriatric Mental State (GMS-A organic 
level).10 The test was administered by trained research assistants. Screen-positive 
subjects had a MMSE score of 25 or less, or a GMS-A score of I or over. In the 
second phase, screen-positive subjects were examined by a Rotterdam Study physician 
with the CAMDEX (Cambridge examination for mental disorders of the elderly) 
diagnostic interview, II which included an interview with an informant. Participants who 
scored less than 80 on the CAMDEX cognitive test or who had higher scores but were 
suspected of dementia clinically were asked to participate in the third examination 
phase. In this diagnostic phase they were examined by a neurologist, had a brain scan 
(by magnetic resonance imaging), and were tested by a neuropsychologist. 
Dementia was diagnosed according to the American Psychiatric Association's 
criteria (DSM-III-R),l2 The subdiagnosis of Alzheimer's disease was based on criteria 
produced by a working group of the National Institute of Neurological and 
COl11l11unicative Disorders and Stroke and the Alzheimer's disease and Related 
Disorders Association (NINCDS-ADRDA).13 For the subdiagnosis of vascular dementia 
the DSM-III-R defmition of multi-infarct dementia was used. The dementia type at the 
onset of the disease was ascertained. Some patients with Alzheimer's disease develop 
symptoms of vascular dementia in the course of the disease, usually after a stroke, 
which may result in a sudden worsening of dementia. 14 We classified these patients as 
Alzheimer's type with cerebrovascular disease. 
A total of 474 cases of dementia was identified.? The present analysis was 
restricted to 284 of those in whom the dementia oruet was less than three years before 
they were examined as part of tlus study. This effectively restricted the analysis to mild 
and moderate cases of dementia in whom the disease is unlikely to have changed the 
atherosclerosis status. In 228 of the 284 dementia patients (80.3 %) the diagnosis was 
based on the CAMDEX and examination by the study neurologist; in 52 cases (18.3 %) 
it was based on MMSE and GMS data; and in 4 cases (1.4 %) the diagnosis was based 
on medical records only. Data on apolipoprotein E were available in 246 of the 
dementia cases. 
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REFERENCE SUBJECTS 
A random sample of 1698 pal1icipants, ranging in age from 55 to 99 years, served as 
conttols. They were selected from the group of pal1icipants of the Rotterdam study who 
were screen-negative for dementia. Data on cardiovascular risk factors and on indicators 
for atherosclerosis were available for all these control participants and data on 
apolipoprotein-E polymorphisms were available for 928 of them. 
MEASUREMENTS 
Presence of atherosclerosis of the carotid arteries (wall thickness and plaques as 
measured by ultra-sonography) and presence of atherosclerosis of the large vessels of 
the legs (assessed by the ratio of the ankle-to-brachial systolic blood pressure) were 
assessed as potential correlates of dementia. 
Ultrasonography of both carotid arteries was performed with a 7.5 MHz linear-
array transducer and a duplex scanner (ATL UltraMark IV, Advanced Teclmology 
Laboratories, Bethel, W A). Intima-media thickness was measured in the common 
carotid arteries as described previously.15 Presence of atherosclerotic plaques, defined as 
a focal widening relative to adjacent segments with protrusion into the lumen, was 
assessed in the common carotid arteries, the bifurcation and the internal carotid 
arteries. 16 The presence of atherosclerosis of the lower extremities was non-invasively 
assessed with the use of ultrasound. The ratio of the ankle-to-brachial systolic blood 
pressure (ankle-brachial 'index) reflects the presence of atherosclerotic vessel wall 
abnormalities of the arteries of the lower extremities and has been shown to be a good 
indicator of generalized atherosclerosis. 17,18 Ankle systolic blood pressure was 
detennined with the subject in supine position at both right and left posterior tibial 
arteries using a Doppler ultrasound transducer with a random-zero sphygmomanometer 
(cuff-size 38 x 14 em). The average of the left and the right ankle-brachial index was 
used in the present analyses. Peripheral arterial disease was considered present when 
left or right ankle-brachial index was less than 0.90. 
Genomic DNA was used for apolipoprotein-E typing. lo The apolipoprotein-E 
gene was amplified using the primers and amplification conditions described by 
Wenham et al.20 After amplification the PCR product was digested with the restriction 
enzyme Hhal and fragments were separated by electrophoresis on a 5% agarose gel. 
Apolipoprotein-E alleles were visualized by ethidium bromide staining. 
Sitting blood pressure was measured at the right upper arm with a random zero 
sphygmomanometer. The average of two measurements obtained on one occasion, 
separated by a count of the pulse rate, was used. Serum total and high density 
lipoprotein (HDL) cholesterol concentrations were determined by an automated 
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enzymatic procedure.21 Body mass index was detennined as body weight (in kg) 
divided by height squared (in m2). 
STATISTICAL ANALYSIS 
The associations between atherosclerosis, apolipoprotein E and dementia were analysed 
in four ways. First, the associations of indicators of atherosclerosis with dementia and 
its subtypes were estimated. To adjust for age and gender differences within the age 
strata, a multiple linear regression model was used, with age and gender added to the 
model. Because of the importance of age as a potential confounder, we added age as a 
continuous variable in years and months to the regression models, and in addition we 
added indicator variables for 5-year age bands to all regression models. The 
associations are presented as odds ratios with 95% confidence intervals. 
Second, a composite measure of atherosclerosis was constlUcted: a point was 
added to the atherosclerosis score if the following characteristics were present: plaques 
in at least one of the common carotid ru1eries, average wall-thickness of common 
carotid arteries in the highest quru1ile of the distribution, and evidence of peripheral 
merial disease, defined as ankle-to-brachial index less than 0.90. This score of 
atherosclerosis was analysed in four categories corresponding to score values of 0-3. 
With a logistic regression model, the odds ratio of each category of atherosclerosis for 
dementia and its subtypes was computed, with age and gender entered into the 
regression model, and with age in 5-year age bands. 
Third, the association between the atherosclerosis score and dementia was 
assessed for subgroups of participants according to apolipoprotein-E polymorphisms; in 
this analysis subjects homozygous for apolipoprotein E3 (83/83 genotype) were 
compared with those with at least one apolipoprotein E4 allele (84'"2, 84/83 and 84/84). 
The results of this analysis are presented as age- and gender-adjusted prevalence 
figures, both by apolipoprotein-E type and atherosclerosis score. 
Fourth, in a fUl1her analysis of the interaction of atherosclerosis and 
apolipoprotein-E genotype, odds ratios are presented in a table with atherosclerosis 
score 2 or 3 and score 0 or I and genotype (homozygous 83, or at least one 84 allele). 
In addition, a regression analysis was perfonned on the full data set with the product 
term for apolipoprotein genotype (in two categories as above) and atherosclerosis (also 
in two categories as above), as assessed with a model which also included both terms 
separately, adjusted for age and gender. The coefficient of the interaction tenn was 
expressed as an odds ratio with a 95% corrfidence interval. 
No major differences in the associations between atherosclerosis and dementia 
were observed between men and women, and therefore the estimates are presented for 
men and women combined. 
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Results 
Of the 284 dementia cases, 82 were male and 202 were female. In 207 (73%) of all 
cases the subdiagnosis was Alzheimer's disease, in 50 (18%) vascular dementia, and in 
27 (10%) other dementia's. Table I presents some characteristics of the demented and 
non-demented subjects. 
All indicators of atherosclerosis were significantly associated with all dementia, 
with odds ratios ranging from 1.3 to 1.9 (table 2). All indicators of atherosclerosis were 
also associated with Alzheimer's disease, with odds ratios ranging from 1.3 to 1.8, and 
with vascular dementia with odds ratios ranging from 1.9 to 3.2 (table· 2). When 
patients classified as Alzheimer's disease with cerebrovascular disease (n~31) were 
excluded from the Alzheimer's disease group, the estimates of the odds ratios remained 
virtually unchanged. 
The apolipoprotein-E 84 allele was associated with all dementia (odds ratio 1.8, 
95% CI 1.2-2.7), Alzheimer's disease (odds ratio 1.7, 95% CI 1.0-2.7) and vascular 
dementia (odds ratio 2.3, 95% CI 1.1-4.8). 
The odds ratio's of all dementia, Alzheimer's disease and vascular dementia 
increased by the score of atherosclerosis (table 2). As shown in the figure, the 
prevalence of all dementia, Alzheimer's disease and vascular dementia by 
atherosclerosis score showed a strong increase in those with the apolipoprotein-E 84 
genotype. 
Table 1. Characteristics of the study subjects. 
Age (yr) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Total cholesterol (mmol/L) 
Body Mass Index (kglm2) 
Men 
Dementia 
(N ~ 82) 
81.2 (59-97)' 
137.7 (24.5) 
74.0 (16.2) 
5.8 (1.1) 
24.8 (3.2) 
No demcntia 
(N ~ 623) 
69.9 (55-94) 
138.1 (20.7) 
72.8 (10.9) 
6.3 (1.2) 
25.9 (3.2) 
Women 
Dementia No dementia 
(N~202) (N~1075) 
84.1 (59-98) 71.9 (55 - 99) 
143.2 (24.6) 138.9 ( 22.4) 
71.1 (14.6) 71.2 (11.6) 
6.3 (1.2) 6.9 (1.3) 
25.7 (4.1) 27.0 (4.3) 
• Values are means and ranges for age, and means and standard deviations for other variables. 
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Table 2. Age-adjusted odds ratios of Alzheimer's disease, vascular dementia and other 
dementias with indicators of atherosclerosis. 
Alzheimer's Vascular Other All 
disease dementia dementias dementia 
(N ~ 207) (N ~ 50) (N ~ 27) (N ~ 284) 
Peripheral arterial disease 1.3 (0.9-1.8) • 2.5 (1.3-4.8) 1.0 (0.4-2.4) 1.5 (1.l-2.0) 
Plaques common carotid 
arteries 1.8 (1.2-2.7) 3.2 (1.6-6.8) 1.6 (0.6-4.3) 1.9 (1.3-2.7) 
Wall thickness common 
carotid arteries t 1.3 (1.0-1.6) 1.9 (1.3-2.8) 0.8 (0.4-1.5) 1.3 (1.l-1.6) 
Atherosclerosis score 
0 (reference) 1.0 1.0 1.0 1.0 
2.2 (1.2-3.9) 1.3 (0.4-4.7) 0.1 (0.0-1.0) 1.6 (1.0-2.7) 
2 2.5 (1.3-4.6) 4.8 (1.6-14.2) 0.6 (0.2-2.4) 2.3 (1.4-3.9) 
3 3.0 (1.5-6.0) 9.5 (3.0-30.0) 0.7 (0.1-3.4) 3.2 (1.8-5.7) 
P-value for trend p < 0.001 P < 0.001 P ~ 0.392 P < 0.001 
• Adjusted for age and gender. with 95% confidence interval in parentheses. 
t Odds ratio of one SD (0.20 n1ln) increase of wall thickness 
Table 3. Age-adjusted odds ratios of Alzheimer's disease, vascular dementia and all dementia 
by atherosclerosis (- it score is 0 or 1; + if score is 2 or 3) and apolipoprotein genotype . 
Genotype • Alzheimer's disease Vascular dementia All dementia 
Atherosclerosis Atherosclerosis Atherosclerosis 
+ + + 
ApoE 33 1.0 1.4 1.0 7.1 1.0 1.6 
(reference) (0.7-3.1) (reference) (1.5-34.3) (reference) (0.8-3.2) 
ApoE 4+ 1.3 3.9 3.6 19.8 1.4 4.5 
(0.6-2.7) (1.6-9.6) (0.8-16.2) (4.1-95.0) (0.7-2.7) (2.0-10.1) 
• ApoE 33: apolipoprotein-E B3/s3 genotype; ApoE 4+: apolipoprotein-E B21B4. B31B4, or B4/s4. 
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Figure. The prevalence of all dementia, Alzheimer's disease and vascular dementia, adjusted 
for age and gender, by apolipoprotcin-E genotype and atherosclerosis score. 
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Subjects with evidence for atherosclerosis (score 2 or 3) and the apolipoprotein-
E 84 genotype had an increased odds for all dementia (odds ratio 4.5; 95% confidence 
interval 2.0-10.1), for Alzheimer's disease (3.9; 1.6-9.6), and for vascular dementia 
(19.8; 4.1-95.0) (table 3). The odds ratio of the interaction term of atherosclerosis and 
apolipoprotein genotype was 2.0 (95% confidence interval 0.7-5.9) for all dementia, and 
2.4 (0.9-7.6) for Alzheimer's disease. 
The observed associations of atherosclerosis and apolipoprotein-E genotype with 
dementia, Alzheimer's disease and vascular dementia were virtually not altered after 
adjustment for blood pressure, total cholesterol and body mass index. 
Discussion 
The main findings in this study are that indicators of atherosclerosis measured at 
different sites are all associated with the presence of dementia, and both of its subtypes, 
Alzheimer's disease and vascular dementia, and that the association between 
atherosclerosis and dementia and its subtypes appears to be pat1icularly strong in those 
with the apolipoprotein-E 84 genotype. Before we can accept these findings some 
methodologic issues have to be addressed. 
This is a cross-sectional study and it is conceivable that changes in the 
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atherosclerotic status have occun'ed as a consequence of dementia, Although we 
consider this unlikely, we further reduced this possibility by restricting our study to 
patients who were recently diagnosed with dementia. Another concern is the 
measurement of atherosclerosis. We used ultrasonographic indicators of atherosclerosis, 
but increased common carotid intima media thickness may not necessarily reflect 
atherosclerosis. It may merely reflect an adaptive response of the vessel wall to changes 
in the sheer stress and tensile stress. However, ultrasonographically determined 
increased wall thickness of the common carotid artery has been associated with 
cardiovascular risk factors.22-24 In addition, progression of wall thickness has been 
associated with risk factors for atherosclerosis.25 This supports the view that non-
invasively assessed intima media thickness of the common carotid attery may be 
regarded as an indicator of atherosclerosis. 
It is likely that some elTor has occun'ed in the measurement of atherosclerosis 
indicators. This may have led to misclassification which tends to underestimate any true 
association between atherosclerosis and dementia, provided that the measurement error 
has occurred to the same extent among the dementia patients and the reference su~jects. 
A strength of our study is that it was population-based and had a relatively high 
response rate. We consider it therefore unlikely that a selection bias may be responsible 
for our fmdings. However, the diagnosis of dementia and in particular its subtypes is of 
concern. A high sensitivity and specificity of the diagnostic procedure was ensured by 
the three phase comprehensive diagnostic work_up.7.8,26.27 Without confirmation at 
necropsy, however, subtyping dementia remains uncertain. Also, the diagnostic criteria 
that were used ,are of limited accuracy, which complicates all large population-based 
dementia studies. A major concem in the present study is the classification of dementia 
patients with cerebrovascular disease. In our main analysis, we classified primary 
Alzheimer's disease complicated by cerebrovascular disease as Alzheimer's disease. 
However, the additional analysis in which cerebrovascular patients were excluded from 
the Alzheimer's group yielded virtually the same results as the main analysis. Although 
we fully cannot exclude diagnostic misclassification enen in this additional analysis, we , 
feel that it supports the view that atherosclerosis is associated with Alzheimer's disease 
perse. 
Our findings suggest that atheroscierosis is not only associated with a small 
subgroup of vascular, or multi infarct dementia, but also with the major subtype of 
dementia, Alzheimer's disease. The findings are in agreement with a recent repOlt that 
suggested a role of p-amyloid peptides in vascular endothelial damage.28 The large 
difference in the prevalence in dementia and Alzheimer's disease between those with 
the apolipoprotein-E 84 allele compared to those with the apolipoprotein-E 83/83 
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genotype by degree of atherosclerosis suggests an intelplay between apolipoprotein E 
and atherosclerosis in the aetiology of Alzheimer's disease. Although addition of 
cardiovascular risk factors like blood pressure and serum lipids to our analysis did not 
change the association between indicators of atherosclerosis and dementia, this does not 
preclude a role of these risk factors in the occurrence of dementia.29 
This population-based study conftnns that the apolipoprotein-E genotype is 
associated with Alzheimer's disease.3.' Our data suggest an interaction between 
atherosclerosis and apolipoprotein E, to the effect that the increase of the prevalence of 
Alzheimer's disease with atherosclerosis is particularly marked in those with the 
apolipoprotein-E 84 genotype?O Unfortunately, these cross-sectional data do not enable 
us to further investigate in which way apolipoprotein E and atherosclerosis interact. 
In conclusion, our observations suggest that atherosclerosis may not only playa 
role in dementia at large, but also in its major subgroup, Alzheimer's disease. The 
association, which was observed with all measured indicators of atherosclerosis, was 
pat1icularly marked in those with the apolipoprotein-E 84 allele. Our findings suggest 
interaction between specific genetic factors and atherosclerosis in the aetiology of 
Alzheimer's disease. 
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Atrial fibrillation and the prevalence of dementia 
Abstract 
Background and Purpose: Atrial fibrillation is a frequent disorder in the elderly and a 
known risk factor of cerebrovascular strokes. We investigated the association of atrial 
fibrillation with dementia and cognitive impairment in a large cross-sectional, 
population-based study in the elderly. 
Methods: Of 6584 patticipants of the Rotterdam Study, aged 55 to 106 years old, 
detailed infonnation on dementia status and electrocardiographic (ECG) abnormalities 
was available. Dementia was diagnosed in three phases. Patticipants were first screened. 
Screenpositive subjects were further tested. Those suspected of dementia undenvent an 
extensive diagnostic work-up. Dementia and dementia subtypes was diagnosed 
according to prevailing criteria. Cognitive impainnent was defined as a Minimental 
State Examination test score of less than 26 points in a non-demented subject. 
Results: Atrial fibrillation was diagnosed in 195, dementia in 276 and cognitive 
impairment in 635 subjects. We found significant positive associations of atrial 
fibrillation with both dementia and impaired cognitive function (age and sex adjusted 
odds ratios of 2.3 (95% CI: 1.4 - 3.7) and 1.7 (95% CI: 1.2 - 2.5), respectively). The 
strongest association was not found for vascular dementia but for patients diagnosed as 
Alzheimer's disease with cerebrovascular disease. The associations were stronger in 
women and the relation with dementia was more pronounced in the relatively younger 
elderly. A history of stroke in subjects with atrial fibrillation could not explain these 
associations. 
Conclusions: Dementia and its subtypes Alzheimer's disease and vascular dementia 
may be related to atrial fibrillation even if no clinical stokes have occurred. 
Introduction 
Atrial fibrillation is a common finding in the elderly. I Patients with atrial fibrillation 
frequently develop cerebral infarctions, which often remain clinically silent.2,3 The 
inefficient cardiac perfOlmance that accompanies atrial fibrillation may result in 
cerebral underperfusion which compromises the ageing brain.4 Though already in 1977 
it was suggested that cardiac dysrythmias could aggravate or even precipitate senile 
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dementia,5 studies on cognitive performance in patients with atrial fibrillation are rare. 
An association with vascular dementia has been suggested but not well quantified. We 
studied the association of atrial fibrillation with dementia, its subtypes and cognitive 
function in a large connnunity-based study. 
SUBJECTS AND METHODS 
The Rotterdam Study is a population-based prospective cohort study investigating the 
occurrence and progression of chronic diseases of the elderly.6 The study focuses on 
neurological, cardiovascular, locomotor and ophthalmologic diseases. All inhabitants of 
Ommoord, a suburb of Rotterdam, aged 55 years and older, including those living in 
institutions, were invited to participate in the study. Of the 10275 eligible subjects, 
7983 (78%) participated in the study. Between 1990 and 1993 all pmlicipants were 
extensively interviewed at their homes and examined at a specially equiped research 
centre in order to collect baseline data and to ascertain health status. Of 577 participants 
no data on cognitive function were available, mostly because of refusal. An additional 
822 subjects had no ECG, usually due to technical or logistic problems. In the present 
analyses 6584 participants (82%) with completed ECG and dementia work-up were 
included. 
EXAMINATIONS 
At their homes pat1icipants were interviewed about their medical history. Subsequently 
they were examined at the research centre. Examinations in institutionalised subjects 
were performed in the institution. All pmlicipants underwent a short neurologic 
examination. Dementia was assessed using a tlu'ce phase approach.7 First, with a 
combined Mini Mental State Examination (MMSE)8 and Geriatric Mental State 
schedule (GMS-A, organic level); the population was screened for dementia. Secondly, 
screen positive subjects (MMSE score below 26 or GMS score above 0) were examined 
by a physician with the Cambridge Examination for Mental Disorders of the Elderly 
(CAMDEX) diagnostic interview,1O which includes an informant interview. Thirdly, all 
independently living, and some institutionalised participants suspected of dementia, 
were invited for examination by the study neurologist (FvH). Upon his indication 
participants were refetTed for a two hour neuropsychologic testing, and brain magnetic 
resonance imaging (MRI), which was obtained in half of the independently living 
patients. Of most institutionalised patients, who were on average older, had more 
physical constraints, and were more severely demented, and of other patients in whom 
the dementia work-up was limited additional infonnation was obtained from medical 
records. A panel consisting of the neurologist, neuropsychologist and the study 
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physician reviewed all available data and made a diagnosis of dementia according to 
Diagnostic and Statistical Manual of mental disorders, edition 3, revised II criteria with 
a subdiagnosis of Alzheimer's disease based on National Institute of Neurological and 
Communicative Disorders and Sh'okelAlzheimer's Disease and Related Disorders 
Association 12 criteria and of vascular dementia in accordance with National Institute of 
Neurological Disorders and Stroke and Association Internationale pour la Recherche et 
,'Enseigllemellt ell Neurosciencesl 3 criteria. Briefly, for the distinction between 
Alzheimer's disease and vascular. dementia, review of the data focused on 
cerebrovascular disorders as detennined by neurologic exam or on MRl scan, their 
relation with the onset of dementia, the acuteness of onset and pattern of progression, 
and the distribution of cognitive defects over the distinct domains of cognition. If a 
cerebrovascular event occurred within 3 months before the onset of dementia, this 
strongly favoured a diagnosis of vascular dementia. The presence of cerebrovascular 
disorders did not prohibit a diagnosis of Alzheimer's disease. In accordance with above 
mentioned NINDS-AIREN criteria Alzheimer's disease patients were subdivided into a 
group without and with cerebrovascular disease. This subdivision was based on 
evidence of strokes or transient ischemic attacks in the medical history, or on cerebral 
MRI. In subjects with the clinical presentation of Alzheimer's disease, a history of 
stroke was considered not directly etiologically related to the dementia if the stroke had· 
occurred defmitely before or after the onset of dementia. 
We defmed cognitive impairment as a MMSE score below 26 in subjects who 
were not demented. 
The presence of atrial fibrillation was assessed in standard 12-lead ECG's, which 
were made at the research centre with an ACTA Gnosis IV ECG recorder 
(EsaotelBiomedica, Florence, Italy) and digitally stored. ECG's were analyzed by the 
Modular ECG Analysis System (MEANS) computer program.14 The program contains a 
module for rhythm classification of the ECG, contour analysis and Minnesota coding. 
Its algorithm calculates ECG diagnoses, which have been shown to be highly reliable. 15 
For this study the program's ECG diagnoses of atrial fibrillation and myocardial 
infarction were used. Myocardial infarction was graded at 4 different levels of certainty 
and was assumed present if the diagnosis was probable or definite. 
Besides myocardial infarction the following possible confounders were 
measured: systolic and diastolic blood pressure, peripheral atherosclerosis, diabetes 
mellitus, education, antihypeltensive, beta-blocker, digoxin, verapamil, anticoagulation 
and thyroid drug treatment. Systolic and diastolic blood pressure were measured with a 
random zero sphygmomanometer. The ankle-to-brachial index (the ratio of the systolic 
blood pressure measured at the ankle and the upper arm) was used as a measure of 
peripheral atherosclerosis: a ratio of 0.9' or below was considered evidence for 
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atherosclerosis.16 Diabetes mellitus was defmed as the use of anti-diabetic medication or 
a random or post-load serum glucose level above II mmoVl. 17 The level of education 
was assessed during the initial home interview and graded in four levels, from primary 
school only to college and higher. Also CUiTent drug use was assessed during the 
interview. Participants were asked to show all medication they were using. Of 
institutionalised subjects, medication was rep0l1ed by the medical staff. We combined 
diuretics with the group of specific antihypertensive drugs. 
Stroke was considered a possible intennediate in the relation between atrial 
fibrillation and cognitive deficits. We only had infOlmation on clinically overt strokes. 
This was determined by asking participants if they ever suffered from a stroke, which 
was diagnosed by a physician. In dementia patients this was asked in the informant 
interview. All histories of stroke were verified with medical records. 
STATISTICAL ANALYSIS 
In the analysis subjects with dementia and those with impaired cognitive function 
without being demented were treated as separate groups. The characteristics of subjects 
with dementia or cognitive impaiIment were compared to those with normal cognition. 
Because the age-distributions in demented and non-demented participants were very 
different we calculated age and sex adjusted differences with multivariate regression 
analysis. 
The association between atrial fibrillation and dementia or cognitive impairment 
was examined by calculating odds ratios by multivariate logistic regression analysis 
with dementia or cognitive impainnent as the dependent, and atrial fibrillation, age and 
sex as independent variables in the model. In the analyses on dementia, subjects with 
cognitive impairment were excluded, and vice versa. We subsequently added 
myocardial infarction, systolic and diastolic blood pressure, peripheral atherosclerosis, 
diabetes mellitus, educational level, antihypertensive medication, beta-blocker, digoxin, 
verapamil, anticoagulation and thyroid drug treatment to the regression model to adjust 
for possible confounding. Missing values on the confounding variables were handled 
with the indicator method. 18 
We repeated the multiple regression analyses in subjects without a history of 
stroke to examine the association of atrial fibrillation with cognitive disorders in the 
absence of clinical strokes. 
To assess whether women with atrial fibrillation had disproportionally more 
vascular comorbidity than men with atrial fibrillation, we performed logistic regression 
analyses with the various vascular detenninants as the dependent and age, sex, atrial 
fibrillation and the product term of sex and atrial fibrillation as independent variables in 
the model. 
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Results 
Of the 6584 participants (age range: 55 to 106 years) in this study, 635 (9.6%) had 
cognitive impairment without dementia, whereas 276 (4.2%) were diagnosed with 
dementia (table 1). In 206 subjects the dementia was of the Alzheimer disease type 
(75%), 41 subjects had vascular dementia (15%), and 29 had other dementias, including 
one undefined dementia (11%). Of the Alzheimer's disease patients, 40 (19%) had 
cerebrovascular disease that was considered not directly related to the dementia. Both 
cognitive impairment and dementia prevalence increased strongly with age." Since the 
prop011ion of women was markedly higher in older age groups, there were relatively 
more women with cognitive disorders. Atrial fibrillation was found in 195 of the 6584 
participants (3.0%) and more frequent in men (3.3%) than women (2.7%). The age-
specific prevalence of atrial fibrillation in men increased from 55 years onward per 10 
year: from 0.9%, 3.0%, 7.6% to 13.2% in those aged 85 and older. In women these 
prevalences were 0.3%, 1.8%, 5.2% and 10.6%. Table 1 gives the age and sex adjusted 
characteristics of subjects with and without cognitive disorders. 
Dementia was more than twice as common in subjects with atrial fibrillation 
than in those without (table 2). We also found a significant positive association between 
cognitive impairment and atrial fibrillation, but this association was less strong. 
Stratification for gender showed that associations were restricted to women. Table 3 
shows that the relation between dementia and atrial fibrillation was modified by age 
and that associations were stronger below 75 years of age in both men and women. No 
such age effect was found for cognitive impairment. Additional adjustments for 
myocardial infarction, blood pressure, peripheral atherosclerosis, diabetes melitus, 
education and various medication, did only slightly change the associations (tables 2,3). 
Only in subjects below 75 years of age the association between dementia and atrial 
fibrillation became smaller when subjects with a history of stroke were excluded. 
Table 4 shows the relation benveen atrial fibrillation and subtypes of dementia. 
Positive associations were observed for both Alzheimer's disease and vascular 
dementia. In particular Alzheimees disease with cerebrovascular disease was strongly 
associated with atrial fibrillation. Additional adjustment for possible confounders 
resulted in reduced odds ratios, but did not essentially change the relation. 
We further explored the gender differences in the association of atrial fibrillation 
with cognitive disordels. If men and women with atrial fibrillation are treated 
differently this could result in variations in the OCCUlTence of complications. Therefore 
we compared treatment regimens between men and women. Similar proportions of men 
and women with atrial fibrillation were treated with digoxin glycosides (38% and 42%, 
respectively) and verapamil (13% and 16%). A larger proportion of men than women 
Table L Characteristics of the study population, dementia patients and subjects with mild cognitive impairment . 
Characteristics No cognitive Dementia Cognitive impainnent Total 
impairment without dementia population 
p-value t p-value t 
Number 5673 276 635 6584 
Age (mean ± sd) 67.9 ± 8.2 83.3 ± 7.3 74.4 ± 9.6 69.2 ± 9.1 
Women (%) 57.7 71.7 67.6 59.2 
Atrial fibrillation (%) 2.1 13 . .0 <0.01 6 . .0 0.01 3 . .0 
ECG Myocardial infarction (%) 8.8 17.1 0.14 8.8 0.17 9.1 
Systolic blood pressure (mmHg, mean ± sd) 138.3 ± 22 . .0 142.8 ± 24.4 <0.01 146.7 ± 24 . .0 <0.01 139.3 ± 22.5 
Diastolic blood pressure (mmHg, mean ± sd) 73.6 ± 11.3 72.1 ± 15 . .0 0.50 74.9 ± 13.4 <0.01 73.7 ± 11.7 
Peripheral atherosclerosis (%) 15.6 5.0.6 <0.01 26.8 0.35 18.3 
Diabetes mellitus (%) 9.9 21.7 0.27 15.5 0.16 11..0 
Only primary education (%) 19.4 66 . .0 <0.01 49.6 <0.01 24 . .0 
Treated with antihypertensives t (%) 22 . .0 41.9 1.00 28.3 0.29 23.4 
Treated with beta-blocking agents (%) 14.7 8.8 <0.01 15.6 0.84 14.6 
Treated with digoxin glycosides (%) 3 . .0 17.7 <0.01 7.1 0.08 3.9 
Treated with verapamil (%) 5.9 1.0.4 0.84 72 0.61 6.2 
Treated. with antithrombotic agents (%) 4.7 9.2 0.22 6.3 0.42 5 . .0 
Treated with thyroid medication (%) 2.2 6.2 0.07 2.7 0.86 2.4 
Stroke history (%) 2.3 14.9 <0.01 5.7 0.02 3.2 
• cognitive impairment was defmed as minimental state examination score below 26 points in non-demented. subjects 
t excludes beta-blocking agents, includes all diuretics, irrespective of the indication 
t sigificance of age and sex adjusted difference with non-impaired subjects 
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TABLE 2. Association of atrial fibrillation to dementia and cognitive impairment by gender. 
Subjects without cognitive impairment were used as the referent category: 
Men 
OR (95%Cl) t 
DemeJllia 
Age and (if applicable) sex adjusted 1.3 (0.5 - 3.1) 
Additional adjustments l 0.8 (0.3 - 2.4) 
Subjects with stroke history excluded 1.2 (0.5 - 3.4) 
Cognitive impairmeJlI witholll demeJllia • 
Age and (if applicable) sex adjusted 1.1 (0.6 - 2.2) 
Additional adjustments f 1.0 (0.5 - 2.1) 
Subjects with stroke history excluded 0.9 (0.4 - 1.9) 
Women 
OR (95%CI) 
3.1 (1.7 - 5.5) 
3.0 (l.5 - 5.9) 
3.0 (1.6 - 5.5) 
2.3 (104 - 3.8) 
2.4 (1.4 - 4.3) 
2.2 (1.3 - 3.7) 
Total population 
OR (95%Cl) 
2.3 (104 - 3.7) 
2.0 (1.2 - 3.4) 
2.3 (104 - 3.8) 
1.7 (1.2 - 2.5) 
1.7 (1.1 - 2.6) 
1.6 (1.0 - 2.4) 
• cognitive impaimlent was defined as minimental state examination score below 26 points in non~ 
demented subjects 
t odds ratio (95 % confidence interval) 
f additional adjustments for ECG myocardial infarction, systolic and diastolic blood pressure, 
peripheral atherosclerosis, diabetes mellitus, education, antihypertensive, beta~blocker, digoxin, 
verapamil, anticoagulation and thyroid dnlg treatment 
used antithrombotic drugs (34% versus 20%). In both men and women without atrial 
fibrillation, 4% indicated to use treatment for irregular haltaction. Of these 28% of men 
and 36% of women used digoxin, 20% of both men and women used verapamil and 
23% of men versus 4% of women used antilhrombotic drugs. There was more vascular 
comorbitity in women than men with atrial fibrillation, and this difference was 
significant for diabetes mellitus, antihypertensive drug use and borderline significant for 
EeG myocardial infarction. 
Discussion 
In this study we found that atrial fibrillation is significantly associated with dementia. 
Particularly women and subjects below age 75 with atrial fibrillation have an increased 
prevalence of dementia. Atrial fibrillation appears to be associated with vascular 
dementia but also with Alzheimer's disease, particularly in cases with concomitant 
cerebrovascular disease. 
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TABLE 3. Association of atr'ial fibrillation with dementia. Subjects without cognitive 
impairment were used as the referent category," 
Age < 75 years 
Age and (if applicable) sex adjnsted 
Additional adjustments t 
SUbjects with stroke history excluded 
Age 2: 75 years 
Age and (if applicable) sex adjusted 
Additional adjustments t 
Subjects with stroke history excluded 
Men 
OR (95%CI) t 
1.9 (0.2 - 15.6) 
4.6 (0.5 - 45.9) 
2.2 (0.3 - 18.2) 
1.2 (0.5 - 3.1) 
0.7 (0.2 - 2.2) 
l.! (0.4 - 3.2) 
Women 
OR (95%CI) 
9.2 (2.5 - 34.3) 
7.1 (1.1 - 45.7) 
3.2 (0.4 - 25.4) 
2.6 (1.4 - 4.8) 
2.6 (1.3 - 5.3) 
2.9 (1.5 - 5.6) 
Total population 
OR (95%CI) 
4.9 (1.7 - 14.7) 
4.4 (1.0 - 18.7) 
2.6 (0.6 - 11.4) 
2.0 (1.2 - 3.4) 
1.8 (1.0 - 3.2) 
2.2 (1.3 - 3.8) 
• non~dcmented subjects with minimental state examination score of 26 points or higher 
t odds ratio (95 % confidence interval) 
f additional adjustments for ECG myocardial infarction, systolic and diastolic blood pressure, 
peripheral atherosclerosis, diabetes mellitus, education, antihypertensive, beta-blocker, digoxin, 
verapamil, anticoagulation and thyroid drug treatment 
TABLE 4. Association between atrial fibrillation and subtypes of dementia. Subjects without 
cognitive impairment were used as the referent category.* 
Age and sex adjusted 
Additional adjustments § 
Alzheimer's disease 
without CVD t 
OR (95% CI) I 
1.8 (1.0 - 3.3) 
1.8 (0.9 - 3.5) 
Alzheimer's disease 
with CVD t 
OR (95% CI) 
4.1 (1.7 - 9.7) 
2.9 (l.! - 7.5) 
Vascular dementia 
OR (95% CI) 
1.9 (0.6 - 5.5) 
1.5 (0.4 - 4.9) 
.. HOH-demented subjects with minim ental state examination score of 26 points or higher 
t cerebra vascular disease 
t odds ratio (95 % confidence interval) 
§ additional adjustments for ECG myocardial infarction, systolic and diastolic blood pressure, 
peripheral atherosclerosis, diabetes mellitus, education, antihypertensive, beta-blocker, digoxin, 
verapamil, anticoagulation and thyroid drug treatment 
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This is a cross-sectional study and there is some potential for bias. Firstly, 18% 
of the Rotterdam Study participants had to be excluded from these analyses due to 
incomplete data. An ECG was more often missing in (especially severely) demented 
pruiicipants and non-responders were on average older than those who could be 
included in the present study. However, we consider it unlikely that the association 
between atrial fibrillation and dementia among non-responders was opposite to what we 
found. Therefore we do not think that non-response has led to essential biases in our 
estimates. Secondly, since our analyses were cross-sectional there is a potential for 
survival effects. If coexisting atrial fibrillation and dementia reduces survival, the 
combination would be seen less and the association would be underestimated. Most 
likely this survival effect is stronger in more severe disease and could have attributed to 
a reduced association in men, in older age and vascular dementia. A third possible bias 
is due to misclassification. Since we used a very sensitive screening for dementia it is 
unlikely that many cases have been missed. Also, the thorough diagnostic work-up 
ensured minimal false positive diagnoses. However, misclassification may have 
OCCUlTed in dementia subtyping. Even though the criteria we used for the diagnosis 
Alzheimer's disease have a high sensitivity and specificity for the autopsy proven 
diagnosis,19 subtyping dementia remains uncertain without post-mortem confirmation or 
additional brain imaging data. Besides, there is increasing evidence that Alzheimer's 
disease and vascular dementia are not as clear entities, nor can be distinguished as 
sharply, as suggested by the common use of these labels. Atrial fibrillation has 
undoubtedly been underdiagnosed. Since only one ECG was recorded, we did not detect 
all paroxysmal atrial fibrillation. In the Cardiovascular Heali Study, a population-based 
study in persons of 65 years and older, it was shown that a IO-second resting ECG (like 
we used) detected 74% of all subjects with atrial fibrillation on 24-hour ambulatory 
electrocardiography.20 Other cardiac alThythmias were in the present analyses also not 
taken into account. Both undetected atrial fibrillation and other al1'hythmias may have 
diluted the association and thus lead to an underestimation of the true effect of atrial 
anhythmias. Finally, in our defmition of cognitive impairment we did not account for 
additional causes of decreased Minhnental State Examination test scores, like depressive 
symptoms, sensory impailTllents and physical disabilities. We consider it however 
unlikely that this has confounded the association between cognitive impairment and 
atrial fibrillation. 
With respect to the stronger association in women than men several hypotheses 
were considered. Antitlu'ombotic drugs are more often prescribed for men and it is 
possible that complications due to atrial fibrillation are more adequately prevented in 
men than women. Women with atrial fibrillation had more coincident cardiovascular 
disorders than men with atrial fibrillation. Two prospective studies on atrial fibrillation 
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in the community showed similar gender differences: both in the Copenhagen City 
Heart Study and in the Framingham Study women with atrial fibrillation had higher 
relative risks of developing a stroke than men.21 .22 It is possible that the combination of 
atrial fibrillation and other cardiovascular disorders is more lethal in men than in 
women. A decreased survival reduces the probability to be detected as demented in a 
cross-sectional study and could explain the reduced association with dementia in the 
oldest group. 
When studying atrial fibrillation as a con'elate of cognition it should be kept in 
mind that atrial fibrillation is often a consequence of underlying cardiac disease. The 
leading causes in the elderly are ischaemic heati disease, hypertension and to a lesser 
extend thyrotoxicosis.4 In less than 8% of the cases in a community-based study no 
causes were found. I Therefore the association with atrial fibrillation could in fact be 
due to the underlying disease. Our results show that adjustment for factors related to 
these diseases, did not weaken the association, and thus plead for an iudependent effect 
of atrial fibrillation on cognition. Atrial fibrillation results iu heamodynamic 
disturbances that might be responsible for braiu lesions: Ineffective atrial clearance 
promotes the fonnation of thrombi. The Framingham Heart Study in 1978 repOlied a 5 
fold iucreased risk of stroke among patients with chronic non-rheumatic atrial 
fibrillation. 23 In OUl' study the age and sex adjusted association of stroke history to atrial 
fibrillation was lower (odds ratio: 1.9, 95%CI: l.l - 3.1), though hypertension was 
often treated and 26% of the atrial fibrillation patients used anti thrombotic medication. 
Two fmdings iu our study indicate that cliuical strokes were no major cause of the 
positive relation of atrial fibrillation with cognitive disorders: Excluding subjects with a 
history of stroke did not result in reduced associations and also vascular dementia was 
not particularly associated with atrial fibrillation. However, silent infarctions may 
underlie the relation between dementia and atrial fibrillation. In previous studies, silent 
infarctions were noticed in 15 - 26% of atrial fibrillation patients,>,24 In a community 
based autopsy series, silent infarctions (13%) were associated with higher age, blood 
pressure and atrial fibrillation. 25 Silent infarctions tend to be small and located deep in 
the brain.24,25 Multiple silent infarctions could very well resemble Alzheimer's disease 
since the few neurologic symptoms that may be found are nonspecific, especially in the 
very old, or alternatively, they could accelerate the conversion of subclinical 
Alzheimer's disease to a conclusive dementia. 
Atrial fibrillation not only results in thromboembolism but also in a reduced 
cardiac output. This reduction is greater at fast ventricular rates and could lead to 
cerebral underperfusion.26 This reduced capacity to maintain adequate brain perfusion, 
could be a second mechanism of brain damage and cognitive decline.27,2' The 
association of white matter lesions to low blood pressure and atrial fibrillation29 
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suggests a heamodynamic etiology. White matter lesions were found cOlTelated with 
reduced cognition28,3o and are about 3 times more prevalent in Alzheimer's disease 
patients than in normal controls.31 •32 Subnormal cardiac output could be one of the 
probably many cerebral affronts that fmally result in the comm011 picture of plaques 
and neurofibrillary tangles.5 
Since the present study was cross-sectional no conclusions can be drawn 
regarding causality. We think our results most likely indicate that atrial fibrillation 
patients have an increased risk of cognitive decline and dementia. Atrial fibrillation was 
been suggested as a risk factor for vascular dementia.33•34 Adequate treatment of atrial 
fibrillation may help prevent multi-infarct dementia33,35 but could also be beneficial for 
those predisposed to develop an Alzheimer's disease type dementia. 
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Chapter 4.3 
Smoking and the risk of dementia and Alzheimer's disease 
Abstract 
Background: Previous studies suggested a protective effect of smoking on Alzheimer's 
disease. These studies were mostly case-control studies based on prevalent cases. 
Prospective studies on the risk of dementia associated with smoking arc scarce and 
inconclusive. 
Methods: We performed a population-based follow-up study of 6870 elderly who were 
initially free of dementia. Smoking histOlY was obtained at baseline and subjects were 
classified as never smokers, former smokers, and cunent smokers. Complete 
ascertainment of cases with incident dementia was pursued. Using never smokers as the 
reference, relative risks were calculated with Cox propOItional hazards regression, 
adjusting for age, sex, education, and alcohol intake. We examined modification by age, 
sex and apolipoprotein E genotype. 
Findings: During an average follow-up of 2.1 years, 146 incident cases of dementia 
were detected, of whom 105 had Alzheimer's disease. Smokers had a more than 
twofold increased risk of dementia (relative risk 2.2, 95% CI 1.3 to 3.6), and 
Alzheimer's disease (relative risk 2.3, 95% CI 1.3 to 4.1). Smoking appeared a strong 
risk factor of Alzheimer's disease in those without the apolipoprotein E4 allele (relative 
risk 4.6, 95% CI 1.5 to 14.2), whereas no effect was observed in subjects with the E4 
allele (relative risk 0.6, 95% CI 0.1 to 4.8). 
Intelpretatioll: This prospective srudy did not confirm results from previous studies, 
which suggested a general protective effect of smoking on dementia and Alzheimer's 
disease. Smoking was associated with a doubling of the risk of dementia and 
Alzheimer's disease. Can·iers of the apolipoprotein E4 allele had no increased risk, 
suggesting interaction between smoking and apolipoprotein E4 genotype in the etiology 
of Alzheimer's disease. 
Introdnction 
Dementia is a frequent disorder with inunense impact on quality of life. Its prevalence 
increases exponentially with age to at least 30% in people aged 85 years and over. I 
Alzheimer's disease and vascular dementia are the major subtypes of dementia, and 
90 Chapter 4.3 
account for about 90% of patients. I Smoking has both been related to vascular dementia 
and Alzheimer's disease. As an important risk factor for cardiovascular diseases,2,3 
smoking is expected to increase the risk of vascular dementia.4 In contrast, an inverse 
association has been observed between smoking and Alzheimer's disease.5 In a study on 
early onset Alzheimer's disease this possible protective effect of smoking was found to 
be limited to caITiers of the apolipoprotein E4 allele.6 Although there are several 
possible explanations for a protective effect of smoking on Alzheimer's disease,5,6 it is 
also conceivable that findings in previous studies were the result of bias.? Also, 
smoking strongly increases mortality and smokers who survive till latcr age may be a 
more selected group than contemporaneous non-smokers.8 
We performed a prospective population-based study of the association of 
cigarette smoking with dementia and Alzheimer's disease, while considering the effects 
of age, sex and the apolipoprotein E genotype. 
Methods 
STUDY DESIGN AND POPULATION 
The Rotterdam Study is a community-based prospective cohOlt study among persons 
aged 55 years and over,9 for which approval was given by the local Medical Ethics 
Committee. All 10275 residents of a suburb of Rotterdam over the age of 55 years 
were eligible and of those 7983 (78%) palticipated and gave informed consent and 
permission to obtain medical information from treating physicians. Baseline 
examinations took place from 1990 to 1993 and comprised a home interview and 
medical examinations at the study centre or, for institutionalized persons, at their 
institution. At baseline, 7528 persons (94%) were evaluated for dementia, I of whom 
474 were diagnosed with dementia and excluded from the present study. Of those 
without dementia an additional 184 were excluded because of missing data on smoking 
history. The remaining 6870 subjects were followed-up for an average of 2.1 years 
(range 1.5-3.4), until the second round of examinations. During this follow-up period 
429 paI1icipants (6.2%) died. Another 962 subjects (14.0%) were not re-examined 
because of refusal or severe illness, Follow-up of all subjects who were not examined 
in person was completed by evaluating their medical files. 
DEMENTIA DIAGNOSIS AND MEASUREMENTS 
For the assessment of dementia the same protocol was used at baseline and at follow-
up, as described in more detail elsewhere. 1,lo Briefly, all subjects were screened with a 
brief test of cognition (Mini Mental State Examination II and the Geriatric Mental State 
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schedule, organic level 12). Screen positives undenvent flll1her cognitive testing, and an 
informant was interviewed on daily functioning of the participant. Persons who were 
suspected of dementia, were examined by a behavioral neurologist, underwent 
neuropsychological testing, and if possible had a brain scan made by magnetic 
resonance imaging.l,lO Of subjects who could not be fe-examined in person, information 
was obtained from general practitioners and the regional institute for outpatient mental 
health care (RIAGG), which covers the entire study population. In the Netherlands, the 
RIAGG is responsible for dementia-care-facility indications. Examinations by the 
RIAGG include (informant) interviews, neurologic and neuropsychologic testing, blood 
biochemistry and syphilis serology. 
The diagnosis of dementia was based on Diagnostic and Statistical Manual of 
mental disorders (DSM-IlI-R) criteria,13 and made by a panel of study physicians, a 
neurologist and a neuropsychologist, which reviewed all existing information. A 
diagnosis of Alzheimer's disease and vascular dementia was based on criteria of the 
National Institute of Neurological and Communicative Disorders and Stroke and 
Alzheimer's Disease and Related Disorders Association (NlNCDS-ADRDA),14 and of 
the National Institute of Neurological Disorders and Stroke and Association 
Intemationale pour la Recherche et I 'Enseignement en Neurosciences (NINDS-
AIREN).15 Alzheimer patients were further classified into those with and without 
cerebrovascular disease. 14 For other dementias, DSM-III-R criteria were used. 13 
Cerebrovascular disease was recognised by history of stroke or transient ischemic 
attack, or by evidence for cerebrovascular lesions on brain scans. 
At baseline, participants were interviewed about the average amount of cigarettes 
smoked, the age at first smoking and, in former smokers, the age at quitting. Subjects 
were also interviewed about attained level of education and alcohol consumption. 
Apolipoprotein E genotyping was performed on coded DNA samples without 
knowledge of the diagnosis. The polymerase chain reaction product was digested with 
the restriction enzyme Hhal, and fragments were separated by electrophoresis. 16 
DATA ANALYSIS 
Cigarette smoking at baseline was categorised into never, fanner and cutTent smoking. 
The number of pack-year exposure was calculated by the average daily number of 
cigarettes divided by 20 and multiplied with the number of years smoked. In all 
analyses never smokers were used as reference category. The relative risk of dementia 
by smoking was calculated with Cox proportional hazards regression, and presented 
with a 95% confidence interval (95% Cl). Since age is a major determinant of dementia 
and age-distributions differed by smoking status, age was adjusted for by including 
linear and squared baseline age in the models. Sex, education and alcohol consumption 
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were judged to possibly confound the association and therefore added to all models. 
Education lVas dichotomized into primmy school or less, and more than primary school. 
Daily alcohol intake, expressed in grammes of pure alcohol per day, was added as 
continuous variable. 
We also investigated whether the smoking related risk of dementia was modified 
by the apolipoprotein E genotype. The apolipoprotein E genotype was available for 122 
of those who developed dementia and a random sample of 1428 non-demented 
participants. Data were analyzed as a nested case-control study using logistic regression 
analysis. Corrections for age, sex, education and alcohol intake were made similarly to 
the above models. Besides, we added duration of follow-up as a continuous variable to 
the regression models. 
Results 
Table I summarizes characteristics of the study population. More than half of all 
women were never smokers, whereas more than half of the men had stopped smoking 
cigarettes (p<0.00005). Smokers were on average younger than never smokers 
(p<0.00005). Never smokers had more often primalY education only (p<0.00005). 
Average daily alcohol intake lVas higher among smokers than non-smokers 
(p<0.00005). 
The mean follow-up period was 2.1 years (range 1.5-3.4), and included 14761 
person-years of observation. We detected 146 incident cases of dementia, of whom 105 
(72%) had Alzheimer's disease and 19 (13%) vascular dementia. Table 2 sholVs that 
TABLE 1. Baseline characteristics of the study population by smoking status. 
Cigarette smoking Total 
Never Fonner Current 
Total studied (n~6870) (%) 39.1 40.1 20.7 
Women (n~4094) (%) 54.6 27.6 17.8 
Men (n~2776) (%) 16.4 58.6 25.0 
Age (years) (SD) 71.9 (9.9) 68.3 (8.0) 66.4 (7.6) 69.3 (9.0) 
Primary education only (%) 31.5 20.2 23.5 25.3 
Alcohol intake (g/day) (SD) 4.2 (8.8) 19.9 (14.6) 12.2 (18.8) 8.1 (14.1) 
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TABLE 2. Relative risk of dementia and dementia subtypes by baseline cigarette smoking: 
Total Alzheimer's disease Vascular Other 
dementia dementia dementias 
Total Without CVD With CVD 
n=146 1l=10S 1l=88 11=17 11=19 n=22 
Never smokers 1.0 1.0 1.0 1.0 1.0 1.0 
(reference) 
Former smokers 1.4 1.3 1.4 1.2 1.4 I.S 
(0.9 - 2.0) (0.8 - 2.1) (0.8 - 2.3) (0.4 - 4.2) (0.5 - 4.4) (0.5 - 4.2) 
Current smokers 2.2 2.3 2.1 3.9 2.2 2.1 
(1.3 - 3.6) (1.3 - 4.1) (1.1 - 4.0) (1.0 - 15.2) (0.6 - 8.4) (0.6 - 6.8) 
• Relative risks with 95% confidence intervals, adjusted for age, sex, alcohol intake, and education. 
CVD = Cerebrovascular disease. 
smokers were at increased risk of dementia, Alzheimer's disease and vascular dementia. 
The relative risk of dementia for CUITent smokers at baseline was somewhat higher in 
persons who died or were not re-examined than in participants who were re-examined 
in person: 2.7 (95% CI 1.2 to 6.0) versus 2.0 (95% ClI.O to 3.7). The mean age at 
onset of dementia for never smokers was 85.5 years. Both former and current smokers 
were on average younger at dementia onset than never smokers (respectively 4.1 years, 
95% CI 1.7 to 6.6; and 8.6 yeat~, 95% CI 5.2 to 12.1). 
The total amount of pack-years smoked was available for 1368 (96%) of CUITent 
smokers and for 2527 (92%) of fOlmer smokers. For current smokers at baseline, the 
relative risk of dementia was 2.5 (95% CI l.l to 5.5) for those who smoked less than 
20 pack-years and 3.0 (95% CI 1.6 to 5.4) for those who smoked 20 pack-years or 
more. For former smokers these figures were 1.5 (95% ClI.O to 2.5) and 2.1 (95% CI 
1.2 to 3.7), respectively. 
The apolipoprotein E4 allele modified the association between smoking and 
dementia (table 3). In subjects without the apolipoprotein E4 allele, smoking increased 
the risk of dementia substantially (relative risk 3.2, 95% CI 1.2 to 8.5). However, 
among carriers of APOE*4, there appeared to be no association between smoking and 
dementia (relative risk lA, 95% CI 0.3 to 5.6). This effect modification was more 
outspoken in Alzheimer patients with an increased relative risk of 4.6 (95% CI 1.5 to 
14.2) for subjects without APOE*4 and a non-significantly decreased relative risk of 
0.6 (95% CI 0.1 to 4.8) in those with APOE*4. 
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TABLE 6. Relative risk of dementia and Alzheimer's disease by baseline cigarette smoking 
and apolipoprotein E4,* 
All dementia Alzheimer's disease 
Apolipoproteill Apolipoprotein Apolipoprotein Apoiipoprotein 
E4 absent E4 present E4 absent E4 present 
(n~73) ('F49) (n~57) (n~33) 
Never smokers 1.0 (reference) 1.0 1.0 1.0 
Fonner smokers 1.9 (0.8-4.6) 1.0 (0.3-3.3) 2.4 (0.9-6.5) 0.9 (0.2-3.6) 
Current smokers 3.2 (1.2-8.5) 1.4 (0.3-5.6) 4.6 (1.5-14.2) 0.6 (0.1-4.8) 
* Relative risks estimated as odds ratios with 95% confidence intervals, adjusted for age, sex, 
alcohol intake, education, and duration of follow~up. 
Discllssion 
In this large prospective population-based study, people who smoked cigarettes were at 
inGreased risk of dementia and Alzheimer's disease. An elevated relative risk was 
pmticularly present for smokers without the apolipoprotein E4 allele. 
The present investigation has several advantages over previous studies on 
smoking and dementia.' Selection bias was avoided because the study was prospective 
and population-based with a high response rate and complete follow-up. As smoking 
habits were assessed before onset of dementia, recall bias is not an issue. Survival bias 
was avoided by including subjects who deceased during follow-up. The somewhat 
higher relative risk of dementia in subjects who died or could not be re-examined 
illustrates that survival bias may indeed have diluted the association of smoking and 
dementia in previous, cross-sectional studies. 
A limitation of the present study is the lack of autopsy confirmation of our 
Alzheimer's disease diagnoses. Another problem is that Alzheimer's disease pathology 
and cerebrovascular disease are often concuncntly present and it may be difficult, both 
clinically and pathologically, to estimate their contribution to the development of 
dementia, IS Although our clinical work-up was extensive and we adhered to commonly 
accepted and reliable criteria, we can not rule out that we misclassified the dementia 
SUbtype in some cases. 
Most previous studies on smoking and dementia used prevalent cases and a case-
control design.' As reviewed by Lee, 4 out of 17 studies reported a significant inverse 
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relation between smoking and Alzheimer's disease.5 Some earlier results may differ 
liOl11 the present findings due to differing methods.? Of particular concem is the 
definition of Alzheimer's disease in the earlier studies. Patients with coexisting vascular 
disease may have been classified as 'mixed' dementia. By excluding these from the 
Alzheimer category, these studies may have selectively cleared cigarette smokers from 
the cases, as smokers are more prone to vascular diseases.2,J However, we found that 
smokers had also an increased risk of Alzheimer's disease without cerebrovascular 
disease. The few studies which estimated the relation with vascular dementia found, as 
we did, a positive association with smoking. 17,18 A few studies have used incident cases 
to assess the risk of Alzheimer's disease by smoking, with varying results. 19.22 
However, none of these looked at a possible effect-modification by apolipoprotein E 
genotype. 
Smoking is a risk factor for vascular disease, including atherosclerosis and 
thrombosis.2•3 Reduction of cerebral perfusion is an acute effect of cigarette smoking, 
and this may be harmful in elderly with a compromised cerebral circulation?3 In the 
pathogenesis of Alzheimer's disease, by far the most common dementing illness, 
vascular involvement is probably more important than previously thought. 24.25 
Van Duijn et al previously repmted that the inverse association between smoking 
and Alzheimer's disease was limited to caI1'iers of the apolipoprotein E4 allele.6 In line 
with that observation we found that the increased risk of dementia and Alzheimer's 
disease associated with smoking was restricted to persons without this allele. If 
atherosclerosis is indeed the intermediate factor in the association between smoking and 
dementia, various explanations could be hypothesized for a modifying effect of 
apolipoprotein E4. Firstly, the presence of the apolipoprotein E4 allele might alter the 
association between smoking and atherosclerosis. However, this was not supp0l1ed by 
OUl' data (not shown). Secondly, the apolipoprotein E4 allele may inhibit the association 
between vascular damage and dementia. This is however in sharp contrast to the 
synergistic effect that we observed between apolipoprotein E4 and atherosclerosis on 
the risk of dementia.25 Thirdly, smoking may exert different and opp'osite effects on the 
risk of Alzheimer's disease, being generally harmful through for example a vascular 
mechanism, but also p311ly beneficial in selected individuals, especially in those who 
CaI1'y an APOE*4 allele. This hypothesis may be supported by the observation that in 
Alzheimer patients can'iers of apolipoprotein E4 have fewer nicotinic receptor binding 
sites and decreased activity of choline acetyltransferasc, as compared to non-c81Tiers of 
this allele.26 Smoking could have some effects on the cholinergic system, which might 
counterbalance the selective impaiIment 
increasing the density of nicotine 
acetylcholine.6•20 
associated with apolipopl'Otein E4, including 
receptors or facilitating the release of 
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In conclusion, we found that for the majority of the population, namely those 
not ca!Tying the apolipoprotein E4 allele, smoking increased the risk of dementia and 
Alzheimer's disease. For subjects with the apolipoprotein E4 allele, however, smoking 
was not associated with an increased risk of dementia. 
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Chapter 5 
General discussion 
This thesis describes studies on the frequency of dementia in the general population and 
the association of dementia with various determinants or possible risk factors. All 
chapters are based on studies performed as prut of the Rotterdam Study, a prospective 
cohort study of residents aged 55 or over, living in the suburb Ommoord of Rotterdam, 
the Netherlands.' The studies in this thesis can be grouped into prevalence (chapters 
2.1; 3.1; 4.1; 4.2) and incidence studies (chapters 2.2; 2.3; 3.2; 4.3). The prevalence 
studies used data obtained at the baseline examinations. We assessed which persons had 
a dementia syndrome and 'cross-sectionally compared characteristics of dementia 
patients with those of non-demented participants. For the incidence studies, we 
monitored pmticipants for the development of dementia afier baseline. This enabled us 
to calculate the risk to become demented, and to study how this risk varied in relation 
to baseline characteristics of participants. 
Major findings 
PREVALENCE STIJDJES 
At baseline 7528 persons were evaluated for the presence of dementia (chapter 2.1). 
This number included 94% of the Rotterdam Study participants and 73% of the eligible 
Ommoord population. Dementia was diagnosed in 474 persons. Dementia prevalence 
increased exponentially with age from 0.4% in the youngest (55-59 years old) to more 
than 40% in the oldest (95+) age category. One-third of the patients had a mild 
dementia, another third was severely demented. Alzheimer's disease was diagnosed in 
72% of all cases, vascular dementia in 16%. The prevalence of dementia appeared 
higher in persons with a low level of education as compared to higher educated. 
Diabetes mellitus (chapter 3.1), measures of atherosclerosis (chapter 4.1), and 
atrial fibrillation (chapter 4.2) were significantly associated with dementia and 
Alzheimer's disease, independently of age and gender. Dementia prevalence increased 
with increasing severity of diabetes or atherosclerosis. Interestingly, the association of 
dementia with atherosclerosis seemed modified by the apolipoprotein-E genotype. The 
84 allele encoding for this protein is repOitedly associated with greater risk for 
Alzheimer's disease. Our results suggest an interaction between apolipoprotein-E and 
atherosclerosis in the etiology of dementia. 
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INCIDENCE STUDIES 
Of 7046 persons who were at risk for dementia, 162 developed a dementia syndrome 
during an average 2.1 years of follow-up, resulting in an overall incidence rate of 
almost II per 1000 person-years (chapter 2.2). Incidence rates increased strongly with 
age. Our results suggested that the increase continues up to high age in women but may 
level off in men around the age of 85. Although age-specific incidence rates were 
largely similar between men and women, due to considerable differences in longevity, 
the lifetime risk for dementia may be twice as high in women than men. According to 
our estimates 33% of 55 year old women will suffer from dementia at the end of their 
life versus 16% of 55 year old men. Low educated women were at double risk for 
dementia as compared to higher educated women (chapter 2.3). No' difference in 
dementia risk by education was observed in men. 
Persons with diabetes mellitus had an age and sex adjusted risk for dementia 
which was almost twice as high as the risk of those without diabetes (chapter 3.2). The 
relative risk (RR) was marginally increased in patients not using antidiabetes 
medication (RR = 1.3), intelmediate in those on oral medication (RR = 2.4), and high 
in patients treated with insulin (RR = 4.3). Diabetes increased the risk of both vascular 
dementia and Alzheimer's disease. 
Persons who smoked cigarettes were at significantly increased risk of dementia 
and Alzheimer's disease (chapter 4.3). This finding is important because case-control 
studies suggested that smoking might protect against Alzheimer's disease. Compared to 
persons who never smoked, people who smoked had a 2.2 times increased risk of 
dementia. The relative risk of ex smokers was 1.4. 
Methodologic considerations 
PREVALENCE STUDIES 
Selection bias 
The most important threat to the validity of our results in the prevalence studies is 
probably selective non-inclusion of subjects in the analyses. We were able to evaluate 
73% of the eligible population for the presence of dementia, which is a good response 
proportion. Still, selective non-response may have biased the estimates based on 
prevalent cases of dementia. 
With respect to the dementia prevalence figures (chapter 2.1) one can only 
speculate about the effect of non-response. In the AMSTEL study non-responders were 
interviewed by their general practitioner and they performed significantly poorer than 
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responders on a cognitive test.2 Non~re:wonders may more often than responders have a 
dementia syndrome and non-response may thus have caused an underestimate of 
dementia prevalence figures. In the study on prevalence of dementia the inclusion rate 
of elderly home residents (80.4%) was slightly higher than of persons living 
independently (72.4%), which was particularly the case for the oldest age groups. As 
cognitive problems are probably more common in institutionalised persons than in those 
living independently,3 this difference in inclusion rate may have led to an overestimate 
of the prevalence in the oldest age-groups. 
Biased association estimates can occur if non-response was dispropOltionate with 
respect to exposure or case status. If for instance an unevenly high propOltion of· 
exposed demented not responded to the study, the association between the exposure and· 
dementia would be underestimated. 
Associations with prevalent cases can lead to false conclusions because of 
differential survival.4,5 Prevalent cases are survivors of previous incidence cohorts and 
cases with slower disease progression will be over-represented. Factors that are 
positively associated with prevalent cases may rather reflect determinants of a milder 
disease type or of better survival. The effect of selective survival has been demonstrated 
before by Ellenberg who showed that under- or overestimate of the odds ratio by 
differential survival equals the inverse odds ratio of the survival proportions.5 If 
survival is disproportionately lower in the exposed demented group, the odds ratio 
between the exposure and dementia is underestimated. In our studies on prevalent cases 
of dementia, differential survival may therefore have influenced the association 
estimates. 
Also selective missing of exposure data may have biased the cross-sectional 
associations. The reliability of interview data obtained fi·om demented subjects can be 
questioned, besides, they were often missing. Other measurements (ECG, blood exam, 
etc.) were also more often missing in cases than in non-demented subjects. Missing data 
were morc common among severely demented subjects than in cases of mild dementia. 
This may have introduced a bias, comparable to survival bias, if the determinants under 
investigation influenced the rate of progression of dementia. 
Diagnostic accuracy 
We used a sensitive screening test to enable detection of very mild (CDR 0.5)6 cases of 
dementia, who may be important for etiologic, prognostic, and future therapeutic studies 
on dementia. Very mild dementia however is not without reason also refened to as 
dubious dementia.6 Patients classified in this category may be wrongly diagnosed 
demented.? During follow-up, in 7 of the 74 velY mild cases the dementia diagnosis 
appeared incOiTect. Mostly, these persons suffered from depression or another 
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psychiatric disorder. On the other hand, with diagnostic information accumulating, we 
later judged that during the prevalence phase we had failed to detect very mild 
dementia in 15 persons. Reassuringly, the mqjority of mild cases tumed out COll'ectly 
diagnosed, as shown by progression of the dementia at follow-up. And our earlier 
prevalence estimates did not change substantially due to the few incorrect diagnoses. 
RepresentahVeness 
Prevalence figures may be used by health care planners to determine the demand of 
specific services. For that purpose it is impOltant to know if the prevalence figures can 
be extrapolated to the entire population. The participating Ommoord population was 
rather representative for the Dutch population but there were differences. The lowest 
and highest socioeconomic classes were slightly under-represented though this unlikely 
influenced the representativeness of the prevalence estimates.' The slightly higher than 
average proportion of very old people in the study cohort is no problem when age-
specific figures are used. Relevant for dementia prevalence estimates is the presence of 
institutionalised elderly in the study cohOlt. Elderly homes which had somatic and 
psychogeriatric nursing wards were well represented. However, the cohort did not 
include a psycho geriatric nursing home and therefore severe dementia may have been 
slightly under-represented. 
INCIDENCE STUDIES 
Selection bias 
A possible threat to incidence studies is bias due to selective loss to follow-up. In our 
study this source of bias was largely avoided by obtaining complete follow-up and 
pursuing complete case-ascertainment. Only 20% of all subjects at risk of dementia 
could not be re-examined in person and had to be evaluated for incident dementia 
through their medical files, reports from general practitioners, and, in some cases, 
informant interviews. The incidence by age curve of re-examined subjects was slightly 
higher than of subjects who were not examined in person, which may suggest that we 
missed some mild cases of incident dementia in the latter group. 
In the incidence studies some subjects had missing risk factol' data. However, as 
these were obtained at baseline before onset of dementia missing data arc a very 
unlikely source of bias in these studies. 
Several studies on the incidence of dementia assessed incidence at follow-up 
among survivors only. Associations with these cases may be affected by differential 
survival. Because we included information on deceased subjects, survival bias is 
unlikely in our studies based on incident cases. 
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Diagnostic accuracy 
As most incident cases of dementia had only mild or very mild disease, the potential 
for misdiagnosis seems greater in incident than prevalent cases. However, at follow-up 
most study subjects had repeated measurements of cognition, enabling detection of 
decline, which probably improved the diagnostic accuracy. Comparison of prevalence 
figures (chapter 2.1) and incidence rates (chapter 2.2), while accounting for differential 
mortality risk between demented and non-demented subjects, showed good agreement 
between both estimates, suggesting a comparable precision of the incidence rates to the 
prevalence figures. Above the age of 85 years however, for men the incidence rates 
levelled off, which was not the case for incidence rates in women, nor lor the 
prevalence of dementia in men. As the number of very old men was small, a few 
undiagnosed cases in this group may already spuriously suggest a levelling off in 
dementia incidence. However, there is an alternative explanation: Similar prevalence at 
high age but lower incidence among very old men than women may result from a 
difference in mortality relative risk. With similar mortality rates for demented men and 
women, but higher overall mOitality for men, the relative risk of dying with dementia 
can be lower in men than women. A lower mortality relative risk of very old demented 
men would explain the relatively high prevalence. 
PREVALENCE - INCIDENCE BIAS 
Education and diabetes mellitus were both studied in relation to prevalent and incident 
cases of dementia. For education we found a strong cross-sectional association with 
dementia in contrast with the minor influence of education on the risk of incident 
dementia (chapters 2.1 and 2.3). Diabetes mellitus was in both cross-sectional and 
longitudinal analyses significantly related to dementia, but the relative risk was 
substantially larger for incident dementia (chapters 3.1 and 3.2). This raises the question 
how these differences can be explained. 
The relation between low education and dementia may have been overestimated 
by the cross-sectional analyses (chapter 2.1). Low educated dementia patients were 
shown to survive longer than higher educated,8 and thus have a higher probability to be 
included in a study on prevalent dementia. Also our data suggested a trend of lower 
mortality relative risk of dementia patients with less education. The age and sex 
adjusted mortality relative risks, obtained with proportional hazards regression, were 
2.0, 2.4, 2.8, and 3.8 respectively in subjects with primary school or less, lower 
vocational education, lower secondary education, and intermediate vocational education 
or higher. Longer survival of lower educated dementia patients is probably due to 
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earlier recognition of the disorder in low educated. Dementia diagnosis is thus 
postponed in higher educated, but their risk of dementia may not be reduced, as 
suggested by our longitudinal study (chapter 2.3). As data on educational level was 
missing in 35% of prevalent dementia patients versus 3% of non-demented subjects, 
selective absence of education data of higher educated dementia patients, who may have 
been in a more progressed dementia stage, could also account for part of the difference 
between the cross-sectional and longi tudinal associations. 
Our data suggest that the association between diabetes and dementia was 
underestimated by the cross-sectional analysis (chapter 3.1). Differential survival may 
have played a role, even though we did not find a difference between diabetes patients 
and subjects without diabetes in the relative mOltality risk for dementia. In both groups 
dementia patients had a 2.4 times increased age and sex adjusted risk to die within the 
follow-up period. Bilt among survivors we noticed a considerable difference between 
the two groups in the relative proportions of non-response to the follow-up 
examinations. Among survivors without diabetes the adjusted relative risk of non-
response for demented subjects was 2.8 (95% CI 2.0-4.0), whereas among diabetes 
patients this relative risk was 5.4 (95% CI 2.8-10.3). A similar disproportionate non-
response in the prevalence phase of the study could explain the weaker cross-sectional 
association between diabetes and dementia. 
SUBTYPING DEMENTIA 
In most previous chapters we discussed the possibility of misdiagnosed dementia 
sUbtype. As we found associations between Alzheimer's disease and all vascular 
detenninants that we investigated, it is tempting to speculate that we misdiagnosed 
vascular dementia as Alzheimer's disease. Contrary to many previous studies we did 
not categorise patients as mixed dementia when both Alzheimer and vascular symptoms 
were present, but tried to determine which disorder was the first or main cause of the 
dementia. Therefore much attention was given to the medical history. Even though 
there are now well-considered and widely accepted criteria for dementia types,9.IO 
sUbdiagnosing remains difficult, in particular if a brain scan, a reliable infonnant 
interview, or neurologic examination are missing. Several previous studies excluded 
patients with vascular disease from the "purel! Alzheimer's disease category, but this 
removes the possibility to study vascular detelTIlinants of the disease. II It is possible 
that Alzheimer brain pathology predisposes to vascular brain damage and inversely, 
vasculopathy and vascular insults could initiate or aggravate Alzheimer-type lesions.'2 
In the general population and at high age, often a mixture of possible causes of 
dementia can be identified. 13 Therefore we can not exclude the possibility that we 
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wrongly subtyped some dementia patients. But we consider it very unlikely that the 
relation we found between vascular determinants and Alzheimer's disease can be fully 
explained by misclassification of dementia subtypes. Given diagnostic difficulties, 
epidemiologic research should not be restricted to Alzheimer's disease, but should 
include all subtypes of dementia. 
Suggestions for future epidemiologic research 
The studies in this thesis indicate that vascular factors are impOltant in the etiology of 
dementia and Alzheimer's disease. New studies on the mechanism how these factors 
cause dementia are needed. Strokes are well recognised as a vascular cause of dementia. 
The possible role of (silent) brain infarctions in Alzheimer's disease needs to be 
disclosed.12 Brain hypoperfusion resulting from atherosclerosis, damage of capillaries, 
and abnormal haemodynamics could be a contributing factor to the Alzheimer's disease 
pathogenesis. To study this hypothesis it would be useful if measures of brain 
circulation and perfusion, suitable for population research, could be identified. They 
might prove important predictors of cognitive decline and dementia. Blood pressure 
disorders could besides inducing strokes also influence brain circulation. Blood pressure 
drop has been shown to be predictive of incident Alzheimer's disease. 14 Therefore, 
blood pressure and the use of antihypertensives should further be studied as 
determinants of dementia, both in relation to and independent of strokes. Major surgery 
(anaesthesia) may critically reduce brain circulation and should thus be studied as risk 
factor for incident cognitive decline and dementia. Other potentially important vascular 
determinants are haemostatic factors and haematocrit. Some indication that haemostasis 
may influence dementia risk came from our prospective study on atrial fibrillation, in 
which patients who used anticoagulant dlUgs had a lower risk of developing dementia 
than those without this medication. 15 NSAIDs, oestrogens, diet, and alcohol use, could 
influence the risk on Alzheimer's disease by a direct mechanism, but the possibility that 
these factors act indirectly, though their effects on vascular determinants, carmot be 
excluded and requires more attention,16,17 
Other vascular and non-vascular variables that may be examined as possible 
determinants of dementia are medical and psychiatric history, the use of specific 
medication, and dietary intake. Associations between dementia and pulmonary disease 
could indicate that decreased blood oxygenation may affect the brain, which would 
provide another clue to the relation of dementia with smoking. In line with above 
remarks, one could speculate that persons with cardiac failure are at increased risk of 
dementia. We found a strong and significant association between digoxin use and 
106 General {HSCIISsiol1 
dementia, which needs un1her attention. A longer follow-up of the existing COh011 and 
additional cases with incident dementia will enable the study of less frequent 
detenninants like psychiatric disease history or specific medication use (like NSAIDs 
and oestrogens):s Some determinants assessed by interview, like family history, intake 
of anti-oxidants, free radicals or other food components,17 can only validly been studied 
in relation to incident dementia. 
New baseline variables could be collected. The association between dementia 
and diabetes mellitus and the recent findings on advanced glycation end-products in 
Alzheimer patients brains (chapter 3.2), prompts to measure these products in study 
participants. The intriguing relations between specific infectious agents and common 
disorders, which used to be thought of as non-infectious, such as peptic ulccr and 
atherosclerosis,19,20 emphasize the need to keep an open mind to possible involvement 
of infectious agents in the etiology of Alzheimer's disease. 
Mass screening for genetic markers of dementia is now possible. Besides the 
apolipoprotein-E gene other susceptibility genes are expected to be identified?1 Most 
likely, the influence of such genetic risk indicators like the apolipoprotein-E &4 allele 
can be modified by environmental factors (chapter 4.1). The study of gene-environment 
interaction in the etiology of dementia will become of much greater relevance. 
There remains uncel1ainty with respect to subtypes of dementia. It would be 
pal1icularly useful to have brain magnetic resonance imaging (MRI) scans of all 
dementia patients in the Rotterdam Study, to enable comparison of clinical observations 
with brain anatomy, This might help to understand the difference or resemblance 
between Alzheimees disease and vascular dementia. Standardised measures of atrophy, 
white matter lesions and infarctions could be con'elated to dementia symptoms, 
subtypes and severity, Attention should be paid to specific location of these lesions 
(hippocampal, medial temporal, (sub )cortical). Comparison of patient MRI scans with 
age matched non-impaired subjects could provide clues to dementia etiology. 
A longer follow-up of study pm1icipants and dementia patients will permit 
studies on prognosis, which may both be of interest to treating physicians and serve 
public health purposes. The development of a risk function for dementia might be 
worthwhile for future intervention studies. 
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Summary 
This thesis contains studies on the risk of dementia, which were perfOlmed as part of 
the Rotterdam Study. 
The Rotterdam Study is a large epidemiologic study on diseases in the elderly. 
The study focuses on chronic disabling diseases. It aims to assess the occurrence of 
these diseases in the general population, and to identify modifiable risk factors. The 
study is situated in Ommoord, a suburb of Rotterdam, the Netherlands. All 10,275 
residents of Ommoord, aged 55 years or over, were invited to participate, and 7983 
(78%) agreed to do so. Informed consent and permission to retrieve information from 
treating physicians was obtained of all pru1icipants. The study started in 1990 and is 
ongoing. With intervals of about 3 years participants are asked to come for 
examinations to the research centre. This thesis describes results from the ftrst two 
rounds of examinations; a third round started in March 1997. During the baseline 
survey, which ended mid 1993, participants were exteruively interviewed and 
examined. The first follow-up examinations took place from September 1993 to the end 
of 1994. From their entrance in the study onwards participants are being monitored for 
the development of various diseases. Through linkage of the general practitioner's 
automated medical record system with the Rotterdam Study data base, occurrence of 
specific diseases is notified to the researchers. All relevant incident disorders are 
verified with the p311icipant's medical files. 
During the baseline survey of the study, we evaluated 7528 persoru for the 
presence of dementia (chapter 2.1). Participants got a short test of cognition. Those 
scoring below the threshold were asked to return for more detailed tests. Persons 
suspected of dementia were refened to a neurologist, and, on indication, undenvent 
neuropsychologic testing, blood examination, and a brain scan. A diagnosis of dementia 
was made by a diagnostic panel according to international criteria. A total of 474 
(6.3%) persons had a dementia syndrome. The proportion of persoru with dementia, the 
prevalence, increased steeply with age from 0.4% of 60 years old persons up to 41 % in 
persons aged 90 years and over. One third of the patients had a mild dementia 
syndrome whereas another third was severely demented. Alzheimer's disease was the 
major dementia subtype (72% of the patients), followed by vascular dementia, mostly 
due to strokes (16%), dementia in patients with Parkinson's disease (6%), and other 
types of dementia (5%). A higher prevalence of dementia was noticed among people 
with a low level of education. Persons with primary school only had a 3 times higher 
dementia prevalence than high educated persons. 
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Study participants without dementia at baseline were followed for, on average, 
2.1 years. Of 7,046 subjects, 162 developed dementia during that period (chapter 2.2). 
The rate at which new dementia develops (incidence) is expressed in cases per 1000 
person-years (pyrs) of follow-up. The overall incidence rate per 1000 pyrs was 10.7 for 
all types of dementia, 7.7 for Alzheimer's disease, and 1.5 for vascular dementia. The 
incidence rate, which is a measure of dementia risk, increased from 0.5 per 1000 pyrs 
at the age of 60 years, to more than 60 per 1000 pyrs in persons of 90 years and over. 
Up to 85 years of age there was no difference in dementia incidence between men end 
women. Above that age the incidence of dementia appeared higher in women than men. 
Women tend to get older than men and are therefore on average during a longer time at 
risk to develop dementia. Fl'Om our data, we estimated that during life 33% of all 
women suffer (to some degree) from dementia, versus 16% of all men. 
Our analyses suggested a relatively stl'Ong relation between education and 
dementia prevalence. We therefore examined if lower educated are at increased risk of 
dementia (chapter 2.3). We found no difference between low and high educated men, 
but women with primary school only had an increased risk of dementia as compared to 
higher educated women. The results from our longitudinal study suggest that previous 
cross-sectional studies may have overestimated the influence of education on dementia 
risk. 
Recent studies showed a correlation between vascular disorders and decreased 
cognitive function. We examined if vascular factors are also related with dementia and 
Alzheimer's disease . 
. We first studied relationships between diabetes mellitus and dementia (chapter 
3.1). Diabetes mellitus was diagnosed by blood glucose measurements or the usage of 
antidiabetes medication. We found a 1.3 times higher prevalence of dementia in 
diabetes patients. This figure (which is an odds ratio (OR» was derived by comparing 
persons with and without diabetes for the presence of dementia, whilst adjusting for 
differences between the groups in age and gender distribution by multiple regression 
analysis. Diabetes mellitus was both associated with vascular dementia and, to a lesser 
degree, with Alzlieimer's disease. The prevalence of dementia was pm1icularly high 
(OR: 3.2) in diabetes patients who were treated with insulin. 
Patients with diabetes and dementia have a relatively high mortality risk. Our 
cl'Oss-sectional study described in chapter 3.1 may therefore have lead to an 
underestimate of the risk diabetes patients run to develop dementia. In chapter 3.2 we 
compared dementia incidence rates of persons with and without diabetes mellitus. In 
this study differences in survival do not influence the results. The risk of diabetes 
patients to get dementia appeared almost twice as high as of people without diabetes. 
The risk increased with severity of diabetes. Patients without antidiabetes medication 
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were at 1.3 times increased risk, those treated with oral anti diabetes medication at 2.4, 
and those on insulin at 4.3 times increased risk of dementia. Besides a positive relation 
with vascular dementia, we found a significant association of diabetes mellitus with 
Alzheimer's disease, suggesting that diabetes may be involved the etiology of the 
disease. We estimated that diabetes mellitus may playa contributing role in almost 9% 
of all dementia OCCUlTing in the population. 
We cross-sectionally examined the relation between dementia and atherosclerotic 
disease (chapter 4.1). Peripheral atherosclerosis, plaques in the carotid mtery, and 
thickening of the carotid mtery vessel wall, were significantly related with dementia, 
particularly with vascular dementia, but also with Alzheimer's disease. Dementia 
prevalence increased with amount of atherosclerosis. Recently, the Apolipoprotein-E 
gene, which encodes for a protein involved in lipid metabolism, was found strongly 
related with Alzheimer's disease. People with the 84 allele of this gene are at increased 
risk of dementia. The exact mechanism is as yet unknown. We found a stronger 
association of atherosclerosis to dementia in persons with the 84 allele as compmed to 
those without, which suggests an intelplay between atherosclerosis and the 
Apolipoprotein-E genotype in the etiology of dementia and Alzheimer's disease. 
We then studied the relation of atrial fibrillation to dementia (chapter 4.2). In 
patients with atrial fibrillation blood circulation is less efficient and a cardiac thrombus 
might form. From this thrombus fragments could come into circulation and cause 
strokes. We found a two fold increased prevalence of dementia in persons with atrial 
fibrillation. The relation existed with vascular dementia, but also with Alzheimer's 
disease, suggesting that atrial fibrillation may cause dementia through other mechanisms 
than clinical strokes. 
We fmally examined the risk of dementia in relation to cigarette smoking 
(chapter 4.3). Previous studies suggested that smoking may reduce the risk of 
Alzheimer's disease. Our study on the incidence of dementia offered good conditions to 
reliably investigate the effect of smoking on dementia. Compared to people who never 
smoked, smokers had twice the risk to develop dementia and Alzheimer's disease. 
Those who had quit smoking still were at a 1.4 times increased risk of dementia. 
Interestingly, we found a clear modifying effect of Apolipoprotein-E genotype. 
Smoking appeared a strong risk factor for dementia and Alzheimer's disease in those 
without the E4 allele, whereas no effect of smoking was observed in subjects with the 
84 allele. 
In chapter 5 we discussed the results of the studies presented in this thesis. We 
conclude that dementia is a frequent disorder, particularly at high age. Alzheimer's 
disease is the most important subtype, followed by vascular dementia. Various vascular 
disorders, of which most are common in the population, were significantly associated 
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with dementia.' Without exception they were also related to Alzheimer's disease, 
suggesting that vascular factors may playa role in the etiology of Alzheimer's disease. 
Further studies should focus on possible mechanisms of how vascular disorders can lead 
to dementia in the absence of major strokes. Prevention of cardiovascular diseases may 
contribute to prevention of dementia and Alzheimer's disease. 
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Samenvatting 
Dit proefschrift beschrijft onderzoek naar het risico op dementie. Het onderzoek werd 
verricht als onderdeel van het Erasmus Rotterdam Gezondheid en Ouderen (ERGO) 
onderzoek. 
Het ERGO onderzoek is een groot epidemiologisch onderzoek naar chronische 
ziekten bij ouderen. Doel van het onderzoek is vast te stellen hoe vaak deze ziekten in 
de bevolking optreden en of ze gerelateerd zijn aan risicofactoren die zich lenen voor 
preventieve maatregelen. Het onderzoek vindt plaats in Ommoord, een buitenwijk van 
Rotterdam. Van aile 10.275 Ommoord bewoners ouder dan 54 jaar die uitgenodigd 
waren aan het onderzoek deel te nemen stemden 7983 (78%) daannee in. Van aile 
deelnemers werd toestemming verkregen medische inforrnatie van behandelend artsen 
op te vragen. Het onderzoek begon in 1990 en duurt nog voort. Ongeveer om de 3 jaar 
worden deelnemers uitgenodigd voor onderzoek naar het ERGO cenltum te komen. Dit 
proefschrift bevat resultaten van de eerste twee onderzoeksrondes. Een derde ronde is in 
maart 1997 gestmt. Gedurende het baseline onderzoek, dat in juli 1993 eindigde, 
werden deelnemers uitgebreid gei'nterviewd en lichamelijk onderzocht. Een eerste 
follow-up onderzoek begon in september 1993 en duurde tot eind 1994. Vanaf het 
begin van de studie zijn deelnemers vervolgd en is het nieuw optreden van bepaalde 
aandoeningen bijgehouden. Dit vond onder andere plaats door koppeling van 
gegevensbestanden van geautomatiseerde huismtsen in Ommoord met het ERGO 
databestand. Relevante nieuw opgetreden aandoeningen bij deelnemers worden 
regelmatig in medische statussen geverifieerd. 
Gedurende het baseline onderzoek zijn 7528 personen onderzocht op dementie 
(hoofdstuk 2.1). Deelnemers ondergingen eerst een kOlte test van de cognitie. Zij die 
onder de drempelwaarde scoorden werden verzocht telUg te komen voor nauwkeuriger 
testen van denkvermogen en geheugen. Personen die na dit onderzoek verdacht werden 
van dementie werden verwezen naar een neuroloog. Op indicatie werd aanvullend 
neuropsychologisch onderzoek gedaan, werd bloed onderzocht en een hersenscan 
gemaakt. Een diagnostisch panel stelde de diagnose dementie en bepaalde tevens het 
subtype volgens intemationale criteria. In totaal bleken 474 (6,3%) personen dementie 
te hebben. De proportie personen met dementie (prevalentie) nam sterk toe met de 
leeftijd van 0.4% bij personen van 60 jaar oud tot 41 % bij 90-plussers. Ongeveer een 
derde van aile patienten had een emstige dementie, een derde leed slechts in geringe 
mate aan dementie. De ziekte van Alzheimer werd in 72% van de patienten 
gediagnosticeerd, vasculaire dementie (meestal het gevolg van beroettes) in 16%, en 
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dementie bij de ziekte van Parkinson in 6%. We vonden een hogere prevalentie van 
dementie bij mensen met een laag opleidingsniveau. Bij personen die niet meer dan 
lager onderwijs hadden genoten werd 3 maal vaker dementie gevonden dan bij hoog 
opgeleiden. 
Deelnemers aan de studie die niet dement waren werden gedurende gemiddeld 
2,1 jaren gevolgd. Van deze 7046 personen ontwikkelden 162 een dementie syndroom 
(boofdstuk 2.2). De incidentie, of weI het aantal nieuwe ziektegevallen gedurende een 
bepaalde tijd, wordt hiema uitgedrukt per 1000 persoonsjaren (incidentiecijfer). Het 
incidentiecijfer was 10,7 voal' dementie; 7,7 VOOI' de ziekte van Alzheimer en 1,5 vaal' 
vasculaire dementie. Het incidentiecijfer, wat cen maat is vaal' het risico op dementie, 
nam toe van 0,5 bij 60-jarigen tot meer dan 60 bij 90-plussers. Tot 85-jarige leeftijd 
vonden we geen verschil tussen mannen en vrouwen; boven die leeftijd leek de 
incidentie van dementie bij vrouwcn hoger dan bij mannen. Vrouwen worden 
gemiddeld ouder dan mannen en lopen daardoor gemiddeld ook langer risico om 
dement te worden. Met behulp van onze gegevens schatten we dat 33% van alle 
vrouwen gedurende hun laatste levensfase aan (enige mate van) dementie zal lijden, en 
16% van alle mannen. 
Het dwarsdoorsnede onderzoek beschreven in hoofdstuk 2.1 liet een relatief sterk 
verband zien tussen opleidingsniveau en de prevalentie van dementie. Daarom 
onderzochten we of lager opgeleiden inderdaad een verhoogd risico hebben op 
dementie. We vanden gcen verschil tussen laag en haag opgeleide mannen, maar 
vrouwen zonder vervolgonderwijs na de lagere school hadden meer kans dementie te 
ontwikkelen dan hoger opgeleide vrouwen (boofdstuk 2.3). 
Recent onderzoek liet een verband zien tussen verminderde cognitie en 
aandoeningen van de bloedvaten. Daarom richtten wij ons onderzoek vervolgens op 
vasculaire risicofactoren vaor dementie en de ziekte van Alzheimer. 
We onderzochten eerst het verband tussen suikerziekte en dementie. Suikerziekte 
werd gediagnosticeerd aan de hand van bloedsuiker bepalingen en medicatie tegen 
suikerziekte. We vanden een 1,3 maal verhoogde dementie prevalentie bij suikerziekte 
patienten (hoofdstuk 3.1). Dit getal, een odds ratio (OR), werd verkregen door het 
voorkomen van dementie te vergelijken bij personen met en zonder suikerziekte. Bias 
door verschil in leeftijd en geslachtsverdeling tussen beide groepen werd voorkomen 
door conectie voor deze variabelen met multipele regressie analyse. Suikerziekte bleek 
geassocieerd met vasculail"e dementie, maar oak, zij het in mindere mate, met de ziekte 
van Alzheimer. Vooral bij suikerziekte patienten die behandeld werden met insuline 
was de prevalentie van dementie hoog (OR: 3,2). 
Personen met suikerziekte en dementie hebben een relatief grote kans om te 
overlijden. Het risico dat suikerziekte patienten lopen dementie te ontwikkelen kan 
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daardaar anderschat worden in een prevalentie anderzaek zaals beschreven in haafdstuk 
3.1. Dam'am hebben we vervalgens het dementie incidentiecijfer vergeleken van de 
graep zander en met suikerziekte (hoofdstuk 3.2). Dit anderzaek geef! een betel' inzicht 
in het effect van suikerziekte ap het ontstaan van dementie. We vanden dat suikerziekte 
het risica ap dementie bijna verdubbelt. Het risica nam toe met de ernst van de 
suikerziekte en was 1,3 keer verhoogd bij patienten zonder medicatie, 2,4 bij patienten 
met orale antidiabetes medicatie, en 4,3 bij patienten behandeld met insuline. Afgezien 
van een positieve relatie met vasculaire dementie was suikerziekte significant 
geassocieerd met de zickte van Alzheimer. Volgens onze schatting zou suikerziekte een 
rol kunnen spelen bij het ontstaan van 9% van aUe dementie in de samenleving. 
We onderzachten vervolgens het verband tussen slagaderverkalking en de 
prevalentie van dementie (hoofdstuk 4.1). Aderverkalking van de beenslagaders, de 
halsslagaders en verdikking van de halsslagaderwand, waren significant gerelateerd met 
dementie, vooral met vasculaire dementie, maar oak met de ziekte van Alzheimer. 
Dementie kwam vakel' voor bij toenemende mate van aderverkalking. Recent is 
gevonden dat het gen voor ApolipoproteYne-E, een eiwit betrokken bij de 
vetstofwisseling, een sterke relatie vertoont met de ziekte van Alzheimer. Mensen met 
het 84 aUel van dit gen hebben een verhoogd risica dement te worden. De oorzaak 
hiervan is vooralsnog onbekend. Wij vonden een sterkel' verband tussen 
slagaderverkalking en dementie bij personen met het 84 allel dan bij personen zonder 
dat allel. Dit suggereert een wisselwerking tussen slagaderverkalking en het 
ApolipoproteYne-E genotype in het ontstaan van dementie en de ziekte van Alzheimer. 
Vervalgens bestudeerden we de relatie tussen atrium fibrilleren en het 
voorkomen van dementie QlOofdstuk 4.2). Ten gevalge van atrium fibrilleren is de 
blaedcirculatie minder efficient en kan een stolsel in het halt ontstaan. Fragmenten 
hiervan kunnen loslaten en een beroerte veroorzaken. Wij vanden dat personen met 
atrium fibrilleren twee keel' zo vaak dement waren dan personen zonder die aandoening. 
Atrium fibrilleren was zowel gerelateerd met vasculaire dementie ais met de ziekte van 
Alzheimer, hetgeen suggereet1 dat er andere mechanismen zijn waardoor atrium 
fibrilleren dementie veroorzaakt dan aileen door klinische beroeltes. 
Tenslotte onderzochten we de relatie tussen dementie en het roken van sigaretten 
QlOofdstuk 4.3). Eerder onderzoek suggereerde dat roken beschelmt tegen de ziekte 
van Alzheimer. Ons dementie" incidentie onderzoek bood goede condities voor een 
betl'Ouwbare analyse van het effect van l'Oken op dementic. Vergeleken met mensen die 
nooit 1'00kten hadden l'Okers een twee keer zo haag risico op dementie en de ziekte van 
Alzheimer. Personen die gestopt waren met roken hadden nog een 1,4 keel' verhaagd 
risico. Een interessante bevinding was dat het ApalipaprateYne-E genotype de relatie 
tussen raken en dementie leek te bernvlaeden. Raken bleek vaaral een duidelijke 
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risicofactor voor dementie bij personen zonder het E4 allel. Daarentegen ondervonden 
dragers van het E4 allel geen effect van roken op het dementie risico. 
In hoofdsluk 5 zijn de resultaten van het onderzoek, beschreven in dil 
proefsclu'ift, besproken. We concluderen dat dementie een veel voorkomende 
aandoening is, vomal op hoge leeftijd. De ziekte van Alzheimer is de meest 
voorkomende vorm van dementie, gevolgd door vasculaire dementie. Diverse vasculaire 
aandoeningen waren significant gerelateerd met dementie. Zonder uitzondering was dat 
ook het geval met de ziekte van Alzheimer, hetgeen suggereelt dat vaataandoeningen 
een rol spelen bij het ontstaan van deze ziekte. Verder onderzoek is nodig om te 
verklaren hoe deze vasculaire aandoeningen tot dementie kunnen leiden bij afwezigheid 
van beroertes. Preventie van hart- en vaatziekten zou kunnen bijdragen aan het 
voork6men van dementie en de ziekte van Alzheimer. 
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